ERLEC1 (also known as XTP3-B or Erlectin) is an ER-resident lectin containing two mannose 6-phosphate receptor homology (MRH) domains. It functions as a context-dependent triage factor in the endoplasmic reticulum-associated degradation (ERAD) pathway, recognizing misfolded glycoproteins via their trimmed N-glycan sugar moieties and delivering them to the HRD1-SEL1L ubiquitin ligase complex for retrotranslocation and proteasomal degradation. The C-terminal MRH domain (MRH2) mediates glycan binding with specificity for Man9GlcNAc2 (M9) and Man5-type high-mannose N-glycans exposing a terminal alpha-1,6-linked mannose motif (DOI:10.1093/glycob/cwp182, DOI:10.1111/febs.12157). ERLEC1 forms a large ER quality control scaffold complex together with OS-9, BiP (HSPA5), and the HRD1-SEL1L ubiquitin ligase. The long isoform (hXTP3-B-long) associates with this scaffold and can retard ERAD of both glycosylated and non-glycosylated substrates, while the short isoform is excluded from scaffold formation. SEL1L stabilizes ERLEC1 protein; SEL1L depletion causes accelerated ERLEC1 degradation (~40% loss over 10 hours in cycloheximide chase) without change in mRNA levels (DOI:10.1111/febs.12157). Genetic studies reveal that ERLEC1 and OS9 play redundant and antagonistic roles in ERAD: both redundantly promote glycoprotein degradation and stabilize SEL1L-HRD1, but ERLEC1 strongly inhibits degradation of non-glycosylated substrates, with OS9 antagonizing this inhibition, thereby tuning ERAD substrate selectivity (DOI:10.1016/j.molcel.2018.03.026). Mannose trimming by ER mannosidase I is required for substrate delivery from EDEM1 to XTP3-B, consistent with its role as a lectin-based ERAD cargo receptor rather than a chaperone.
| GO Term | Evidence | Action | Reason |
|---|---|---|---|
|
GO:0005788
endoplasmic reticulum lumen
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: IBA annotation placing ERLEC1 in the ER lumen, inferred from phylogenetic analysis. This is strongly supported by multiple independent experimental studies. Cruciat et al. (PMID:16531414) showed that Erlectin is a luminal resident protein of the endoplasmic reticulum. Hosokawa et al. (PMID:18502753) confirmed ER lumen localization. Christianson et al. (PMID:18264092) also demonstrated ER lumen localization. UniProt annotates subcellular location as ER lumen with experimental evidence. ERLEC1 has a signal peptide (aa 1-33) and lacks a transmembrane domain, consistent with a soluble ER lumen protein retained by the quality control machinery.
Reason: ER lumen localization is a core feature of ERLEC1 function as an ERAD cargo receptor. The IBA annotation is fully consistent with multiple experimental (IDA) demonstrations of ER lumen localization.
Supporting Evidence:
PMID:16531414
Like other members of the MRH family, Erlectin is a luminal resident protein of the endoplasmic reticulum
PMID:18502753
hXTP3-B long isoform associates with the HRD1-SEL1L membrane-anchored ubiquitin ligase complex and BiP, forming a 27 S ER quality control scaffold complex
|
|
GO:0030970
retrograde protein transport, ER to cytosol
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: IBA annotation for involvement in retrograde protein transport, ER to cytosol, inferred from phylogenetic analysis including yeast Yos9p. ERLEC1/XTP3-B is a key component of the ERAD pathway that delivers misfolded glycoproteins to the HRD1-SEL1L ubiquitin ligase complex for retrotranslocation and proteasomal degradation (PMID:18264092, PMID:18502753). Hosokawa et al. (PMID:18502753) showed that ERLEC1 forms a scaffold complex that provides a platform for recognition and sorting of misfolded proteins prior to retrotranslocation into the cytoplasm. Groisman et al. (PMID:21062743) demonstrated that mannose trimming is required for substrate delivery from EDEM1 to XTP3-B and to late ERAD steps. This term is appropriate as ERLEC1 participates in the process that moves ER proteins to the cytosol for degradation.
Reason: Retrograde protein transport ER to cytosol is a core process that ERLEC1 participates in as an ERAD cargo receptor. The IBA annotation is well supported by experimental evidence from multiple groups showing ERLEC1 functions in delivering misfolded substrates to the retrotranslocation machinery.
Supporting Evidence:
PMID:18502753
this large ER quality control scaffold complex, containing ER lectins, a chaperone, and a ubiquitin ligase, provides a platform for the recognition and sorting of misfolded glycoproteins as well as nonglycosylated proteins prior to retrotranslocation into the cytoplasm for degradation
PMID:18264092
OS-9 and XTP3-B/Erlectin are ER-resident glycoproteins that bind to ERAD substrates and, through the SEL1L adaptor, to the ER-membrane-embedded ubiquitin ligase Hrd1
PMID:21062743
Our results suggest that mannose trimming enables delivery of a substrate glycoprotein from EDEM1 to late ERAD steps through association with XTP3-B
|
|
GO:0005783
endoplasmic reticulum
|
IEA
GO_REF:0000117 |
ACCEPT |
Summary: IEA annotation from ARBA machine learning placing ERLEC1 in the endoplasmic reticulum. This is correct but less specific than GO:0005788 (endoplasmic reticulum lumen), which is supported by IDA evidence from multiple publications (PMID:16531414, PMID:18264092) and IBA evidence. ERLEC1 is a soluble ER lumen protein, not a membrane-associated protein, so the more specific ER lumen term is more appropriate. However, as an IEA annotation, it is acceptable to retain a broader term that is not incorrect.
Reason: While GO:0005783 (endoplasmic reticulum) is less specific than the experimentally supported GO:0005788 (ER lumen), it is not incorrect. The IEA annotation is a broader but valid computational inference. The more specific ER lumen localization is already captured by separate IDA and IBA annotations.
|
|
GO:0005788
endoplasmic reticulum lumen
|
IEA
GO_REF:0000044 |
ACCEPT |
Summary: IEA annotation mapping ERLEC1 to the ER lumen based on UniProtKB/Swiss-Prot subcellular location vocabulary. UniProt annotates ERLEC1 subcellular location as "Endoplasmic reticulum lumen" with experimental evidence from PMID:16531414 and PMID:18502753. This computational mapping is fully consistent with the experimental data.
Reason: The IEA mapping from UniProt subcellular location to GO:0005788 is correct and consistent with experimental evidence. ERLEC1 ER lumen localization is well established.
|
|
GO:0030968
endoplasmic reticulum unfolded protein response
|
IEA
GO_REF:0000002 |
MODIFY |
Summary: IEA annotation from InterPro (IPR045149, OS-9-like domain) mapping to the ER unfolded protein response. ERLEC1 is part of the ER quality control machinery but its primary role is in ERAD, not the canonical unfolded protein response (UPR) signaling pathway. The UPR is a transcriptional signaling response involving IRE1, PERK, and ATF6 pathways that activates gene expression to cope with ER stress. ERLEC1 does not participate in UPR signaling; rather, it functions downstream as a cargo receptor in ERAD, recognizing misfolded glycoproteins and delivering them to the HRD1-SEL1L complex for retrotranslocation (PMID:18264092, PMID:18502753). The ERAD pathway annotation (GO:0036503) is the more precise term.
Reason: GO:0030968 (ER unfolded protein response) refers to the UPR signaling cascade, not to ERAD per se. ERLEC1 is not a UPR signaling component but rather an ERAD cargo receptor. The correct biological process term is GO:0036503 (ERAD pathway), which is already annotated separately. This IEA annotation likely arises from an overly broad InterPro-to-GO mapping for the OS-9-like domain family.
Proposed replacements:
ERAD pathway
|
|
GO:0036503
ERAD pathway
|
IEA
GO_REF:0000002 |
ACCEPT |
Summary: IEA annotation from InterPro (IPR045149, OS-9-like) mapping to the ERAD pathway. This is fully supported by extensive experimental evidence. ERLEC1/XTP3-B is a central component of the ERAD pathway, functioning as a lectin-based cargo receptor that recognizes misfolded glycoproteins and delivers them to the HRD1-SEL1L ubiquitin ligase complex (PMID:18264092, PMID:18502753, PMID:21062743). Groisman et al. (PMID:21062743) specifically demonstrated that mannose trimming is required for substrate delivery from EDEM1 to XTP3-B and to late ERAD steps. Christianson et al. (PMID:18264092) showed that XTP3-B binds to ERAD substrates and through SEL1L to HRD1, and is required for degradation of mutant alpha1-antitrypsin.
Reason: The ERAD pathway is the core biological process in which ERLEC1 participates. The IEA annotation is correct and well supported by experimental evidence from multiple independent studies.
|
|
GO:0036503
ERAD pathway
|
TAS
PMID:21062743 Mannose trimming is required for delivery of a glycoprotein ... |
ACCEPT |
Summary: TAS annotation for ERAD pathway involvement based on Groisman et al. (PMID:21062743). This paper directly demonstrates that XTP3-B functions in the ERAD pathway by showing that mannose trimming by ER mannosidase I is required for substrate delivery from EDEM1 to XTP3-B, and that inhibition of mannose trimming blocks substrate association with XTP3-B and with E3 ubiquitin ligases HRD1 and SCF(Fbs2). This establishes ERLEC1 as a lectin acting at a late step in the ERAD pathway, after mannose trimming and before ubiquitination and retrotranslocation.
Reason: ERAD pathway involvement is the core function of ERLEC1. The TAS annotation is well supported by the cited reference, which directly demonstrates ERLEC1 function in delivering substrates to late ERAD steps in a mannose-trimming-dependent manner.
Supporting Evidence:
PMID:21062743
Our results suggest that mannose trimming enables delivery of a substrate glycoprotein from EDEM1 to late ERAD steps through association with XTP3-B
PMID:21062743
substrate association with XTP3-B and with the E3 ubiquitin ligases HRD1 and SCF(Fbs2) was inhibited
|
|
GO:0051082
unfolded protein binding
|
IDA
PMID:21062743 Mannose trimming is required for delivery of a glycoprotein ... |
REMOVE |
Summary: GO:0051082 (unfolded protein binding) is being obsoleted (go-ontology#30962). The suggested replacements are holdase chaperone activity or protein folding chaperone (GO:0044183), neither of which applies to ERLEC1. ERLEC1/XTP3-B is an ER lectin that recognizes misfolded glycoproteins via their trimmed N-glycan moieties as part of the ERAD pathway (PMID:21062743, PMID:18502753). It is not a chaperone. Groisman et al. (PMID:21062743) showed that mannose trimming by ER mannosidase I is required for substrate delivery from EDEM1 to XTP3-B, establishing ERLEC1 as a lectin-based cargo receptor rather than a protein that directly binds unfolded polypeptide chains. Christianson et al. (PMID:18264092) demonstrated that the MRH domains of XTP3-B are required for interaction with SEL1L but not with substrate, and that XTP3-B and OS-9 are components of quality control surveillance pathways that coordinate protein folding with membrane dislocation and ubiquitin conjugation. Hosokawa et al. (PMID:18502753) showed that hXTP3-B forms a scaffold with HRD1-SEL1L and BiP, and that the long isoform retarded ERAD of both glycosylated (NHK) and non-glycosylated (NHK-QQQ) substrates. While ERLEC1 does interact with misfolded proteins, this interaction is in the context of ERAD substrate recognition and delivery to the ubiquitin ligase complex, not chaperone-like unfolded protein binding. The ERAD pathway involvement is already captured by GO:0036503.
Reason: GO:0051082 is being obsoleted. The replacement terms (holdase chaperone, foldase chaperone) do not apply to ERLEC1, which is a lectin-based ERAD cargo receptor, not a chaperone. ERLEC1 recognizes misfolded glycoproteins through their N-glycan sugar moieties (requiring mannose trimming) and delivers them to the HRD1-SEL1L ubiquitin ligase complex for degradation. This is substrate recognition for ERAD targeting, not chaperone-like binding to unfolded polypeptide chains. The relevant biological function is already captured by the ERAD pathway annotation (GO:0036503) and retrograde protein transport annotation (GO:0030970). Similar to SYVN1, ERLEC1 interacts with misfolded proteins as part of the ERAD machinery, which does not constitute unfolded protein binding in the chaperone sense.
Supporting Evidence:
PMID:21062743
Our results suggest that mannose trimming enables delivery of a substrate glycoprotein from EDEM1 to late ERAD steps through association with XTP3-B
PMID:21062743
substrate association with XTP3-B and with the E3 ubiquitin ligases HRD1 and SCF(Fbs2) was inhibited
PMID:18264092
OS-9 and XTP3-B/Erlectin are ER-resident glycoproteins that bind to ERAD substrates and, through the SEL1L adaptor, to the ER-membrane-embedded ubiquitin ligase Hrd1
PMID:18264092
Both proteins contain conserved mannose 6-phosphate receptor homology (MRH) domains, which are required for interaction with SEL1L, but not with substrate
PMID:18264092
XTP3-B and OS-9 are components of distinct, partially redundant, quality control surveillance pathways that coordinate protein folding with membrane dislocation and ubiquitin conjugation in mammalian cells
PMID:18502753
hXTP3-B long isoform associates with the HRD1-SEL1L membrane-anchored ubiquitin ligase complex and BiP, forming a 27 S ER quality control scaffold complex
PMID:18502753
this large ER quality control scaffold complex, containing ER lectins, a chaperone, and a ubiquitin ligase, provides a platform for the recognition and sorting of misfolded glycoproteins as well as nonglycosylated proteins prior to retrotranslocation into the cytoplasm for degradation
PMID:16531414
Erlectin functions in N-glycan recognition in the endoplasmic reticulum, suggesting that it may regulate glycoprotein traffic
|
|
GO:1904153
negative regulation of retrograde protein transport, ER to cytosol
|
IMP
PMID:25660456 Identification of ERAD components essential for dislocation ... |
KEEP AS NON CORE |
Summary: IMP annotation for negative regulation of retrograde protein transport (ER to cytosol) based on Zhong et al. (PMID:25660456). This paper used RNAi knockdown and a dislocation-reconstituted GFP (drGFP) assay to assess the requirement of ERAD components for dislocation of NHK (null Hong Kong variant of alpha1-antitrypsin). The study found that knockdown of 7 of 21 ERAD components enhanced NHK dislocation. If ERLEC1 knockdown enhanced dislocation, this would be consistent with a negative regulatory role. However, this seemingly contradicts the established role of ERLEC1 as a facilitator of ERAD (delivering substrates to the ubiquitin ligase). Hosokawa et al. (PMID:18502753) showed that overexpression of the long isoform of hXTP3-B retarded ERAD of both NHK and NHK-QQQ, which is consistent with a negative regulatory effect when in excess. This paradoxical role may reflect that excess ERLEC1 sequesters substrates or blocks the retrotranslocation channel. The annotation captures the experimental observation but should be interpreted cautiously as possibly reflecting an overexpression/dosage artifact rather than a normal physiological function.
Reason: The annotation captures a real experimental observation (IMP evidence) but the negative regulation of retrotranslocation is likely not the primary physiological role of ERLEC1. Its core function is as a cargo receptor that facilitates ERAD. The negative regulatory effect may reflect dosage-dependent or context-dependent modulation. Hosokawa et al. (PMID:18502753) also observed that hXTP3-B overexpression retards ERAD, consistent with a scaffolding role where excess cargo receptor can sequester substrates away from the retrotranslocation machinery.
Supporting Evidence:
PMID:25660456
knockdown of 7 of the 21 components enhanced NHK dislocation
PMID:18502753
both isoforms retard ERAD of the human alpha(1)-antitrypsin variant null Hong Kong (NHK), a terminally misfolded glycoprotein
PMID:18502753
The hXTP3-B long isoform strongly inhibited ERAD of NHK-QQQ, which lacks all of the N-glycosylation sites of NHK
|
|
GO:0044322
endoplasmic reticulum quality control compartment
|
TAS
Reactome:R-HSA-5362412 |
ACCEPT |
Summary: TAS annotation from Reactome (R-HSA-5362412: SYVN1 ubiquitinates Hh C-terminal fragments) placing ERLEC1 in the ER quality control compartment (ERQC). The ERQC is a pericentriolar ER-derived compartment where ERAD machinery concentrates along with misfolded substrates. Groisman et al. (PMID:21062743) showed that XTP3-B associates with ERAD substrates and E3 ligases in a mannose-trimming-dependent manner, consistent with localization to the ERQC. The Reactome entry describes ERLEC1 as a lectin in the ERAD machinery that helps target Hedgehog C-terminal fragments for degradation. This is a reasonable localization annotation for ERLEC1 given its role in ERAD substrate recognition.
Reason: ERQC localization is consistent with ERLEC1 function in ERAD. As a cargo receptor that concentrates with ERAD machinery and substrates, ERLEC1 localizes to this quality control compartment. Multiple Reactome entries reference the same biological role; this is one of many duplicate TAS annotations from different Reactome reactions.
Supporting Evidence:
PMID:21062743
substrate association with XTP3-B and with the E3 ubiquitin ligases HRD1 and SCF(Fbs2) was inhibited
|
|
GO:0044322
endoplasmic reticulum quality control compartment
|
TAS
Reactome:R-HSA-5362437 |
ACCEPT |
Summary: TAS annotation from Reactome (R-HSA-5362437: C-terminal Hh fragments are bound by lectins). This Reactome entry explicitly states that depletion of OS9 and ERLEC1 abrogates degradation of Hh-C fragments, and that they may target Hh-C to the retrotranslocation channel via interaction with SEL1. ERQC localization is appropriate for ERLEC1 given its established role as an ERAD lectin cargo receptor.
Reason: Duplicate ERQC localization annotation from a different Reactome reaction. Same rationale as for R-HSA-5362412: ERLEC1 localizes to the ERQC as part of its ERAD cargo receptor function.
|
|
GO:0044322
endoplasmic reticulum quality control compartment
|
TAS
Reactome:R-HSA-5362441 |
ACCEPT |
Summary: TAS annotation from Reactome (R-HSA-5362441: C-terminal Hh fragments are recruited to SEL1:SYVN1 at the ER membrane). ERLEC1 participates in recruiting substrates to the SEL1L-SYVN1 complex at the ER membrane, consistent with ERQC localization.
Reason: Duplicate ERQC localization annotation from a different Reactome reaction describing the same ERAD process for Hh fragments.
|
|
GO:0044322
endoplasmic reticulum quality control compartment
|
TAS
Reactome:R-HSA-5362450 |
ACCEPT |
Summary: TAS annotation from Reactome (R-HSA-5362450: Hh processing variants bind lectins). This entry describes how OS9 and ERLEC1 lectins are required for degradation of Hh processing-defective variants via the ERAD pathway, consistent with ERQC localization.
Reason: Duplicate ERQC localization annotation from a different Reactome reaction describing ERAD of Hedgehog processing variants.
|
|
GO:0044322
endoplasmic reticulum quality control compartment
|
TAS
Reactome:R-HSA-5362459 |
ACCEPT |
Summary: TAS annotation from Reactome (R-HSA-5362459: VCP-catalyzed ATP hydrolysis promotes the translocation of Hh-C into the cytosol). ERLEC1 is part of the ERAD machinery that operates within the ERQC.
Reason: Duplicate ERQC localization annotation from a Reactome reaction describing the VCP-dependent retrotranslocation step for Hh-C fragments in which ERLEC1 participates upstream.
|
|
GO:0044322
endoplasmic reticulum quality control compartment
|
TAS
Reactome:R-HSA-5387386 |
ACCEPT |
Summary: TAS annotation from Reactome (R-HSA-5387386: Hh processing variants are recruited to SEL1:SYVN at the ER membrane). ERLEC1 participates in recruiting Hh processing variants to the ubiquitin ligase complex.
Reason: Duplicate ERQC localization annotation from a Reactome reaction. Same biological context as other Hh ERAD entries.
|
|
GO:0044322
endoplasmic reticulum quality control compartment
|
TAS
Reactome:R-HSA-5387389 |
ACCEPT |
Summary: TAS annotation from Reactome (R-HSA-5387389: Hh processing variants are translocated to the cytosol in a VCP-dependent manner). Part of the Hh ERAD pathway in which ERLEC1 acts as cargo receptor.
Reason: Duplicate ERQC localization annotation from a Reactome reaction in the Hh ERAD pathway.
|
|
GO:0044322
endoplasmic reticulum quality control compartment
|
TAS
Reactome:R-HSA-5483238 |
ACCEPT |
Summary: TAS annotation from Reactome (R-HSA-5483238: Hh processing variants are ubiquitinated). ERLEC1 functions upstream of the ubiquitination step in ERAD, within the ERQC.
Reason: Duplicate ERQC localization annotation from a Reactome reaction describing Hh variant ubiquitination in which ERLEC1 participates.
|
|
GO:0044322
endoplasmic reticulum quality control compartment
|
TAS
Reactome:R-HSA-8866542 |
ACCEPT |
Summary: TAS annotation from Reactome (R-HSA-8866542: VCP-catalyzed ATP hydrolysis promotes the translocation of misfolded CFTR into the cytosol). ERLEC1 is part of the ERAD machinery for misfolded CFTR, consistent with ERQC localization.
Reason: Duplicate ERQC localization annotation from a Reactome reaction describing CFTR ERAD in which ERLEC1 participates as cargo receptor.
|
|
GO:0044322
endoplasmic reticulum quality control compartment
|
TAS
Reactome:R-HSA-8866546 |
ACCEPT |
Summary: TAS annotation from Reactome (R-HSA-8866546: RNF5 and RNF185 ubiquitinate misfolded CFTR). ERLEC1 operates within the ERQC as part of the CFTR ERAD pathway.
Reason: Duplicate ERQC localization annotation from a Reactome reaction in the CFTR ERAD pathway.
|
|
GO:0044322
endoplasmic reticulum quality control compartment
|
TAS
Reactome:R-HSA-8866551 |
ACCEPT |
Summary: TAS annotation from Reactome (R-HSA-8866551: CFTR binds components of the ERAD machinery for ubiquitination and degradation). ERLEC1 is one of the ERAD components that binds misfolded CFTR in the ERQC.
Reason: Duplicate ERQC localization annotation from a Reactome reaction describing CFTR binding to ERAD components including ERLEC1.
|
|
GO:0044322
endoplasmic reticulum quality control compartment
|
TAS
Reactome:R-HSA-8866854 |
ACCEPT |
Summary: TAS annotation from Reactome (R-HSA-8866854: VCP-catalyzed ATP hydrolysis promotes the translocation of CFTR F508del into the cytosol). ERLEC1 participates in ERAD of the common CF-causing CFTR F508del mutation, within the ERQC.
Reason: Duplicate ERQC localization annotation from a Reactome reaction in the CFTR F508del ERAD pathway.
|
|
GO:0044322
endoplasmic reticulum quality control compartment
|
TAS
Reactome:R-HSA-8866856 |
ACCEPT |
Summary: TAS annotation from Reactome (R-HSA-8866856: RNF5 and RNF185 ubiquitinate CFTR F508del). ERLEC1 is part of the ERAD machinery for CFTR F508del within the ERQC.
Reason: Duplicate ERQC localization annotation from a Reactome reaction in the CFTR F508del ERAD pathway.
|
|
GO:0044322
endoplasmic reticulum quality control compartment
|
TAS
Reactome:R-HSA-8866857 |
ACCEPT |
Summary: TAS annotation from Reactome (R-HSA-8866857: CFTR F508del binds components of the ERAD machinery for ubiquitination and degradation). ERLEC1 is an ERAD component that binds misfolded CFTR F508del.
Reason: Duplicate ERQC localization annotation from a Reactome reaction describing CFTR F508del ERAD.
|
|
GO:0044322
endoplasmic reticulum quality control compartment
|
TAS
Reactome:R-HSA-9931264 |
ACCEPT |
Summary: TAS annotation from Reactome (R-HSA-9931264: Active transport of ubiquitinated CD274 from ER to cytosol). ERLEC1 participates in ERAD of CD274 (PD-L1) within the ERQC.
Reason: Duplicate ERQC localization annotation from a Reactome reaction describing CD274 ERAD.
|
|
GO:0044322
endoplasmic reticulum quality control compartment
|
TAS
Reactome:R-HSA-9931298 |
ACCEPT |
Summary: TAS annotation from Reactome (R-HSA-9931298: Ubiquitination of CD274 by ERAD complex). ERLEC1 is part of the ERAD complex that ubiquitinates CD274.
Reason: Duplicate ERQC localization annotation from a Reactome reaction describing CD274 ubiquitination by ERAD.
|
|
GO:0044322
endoplasmic reticulum quality control compartment
|
TAS
Reactome:R-HSA-9931313 |
ACCEPT |
Summary: TAS annotation from Reactome (R-HSA-9931313: p-S195-CD274 binds ERAD complex). ERLEC1 is part of the ERAD complex that binds phosphorylated CD274 for degradation.
Reason: Duplicate ERQC localization annotation from a Reactome reaction describing CD274 ERAD. Last of the 16 duplicate Reactome TAS annotations for ERQC localization, all consistent with ERLEC1 role in ERAD.
|
|
GO:0005515
protein binding
|
IPI
PMID:18502753 Human XTP3-B forms an endoplasmic reticulum quality control ... |
MODIFY |
Summary: IPI annotation for protein binding based on Hosokawa et al. (PMID:18502753), with UniProtKB:Q13438 (OS-9/OS9) as the interacting partner. This paper showed that hXTP3-B forms an ER quality control scaffold complex with OS-9, HRD1-SEL1L, and BiP. The interaction between ERLEC1 and OS-9 is in the context of the ERAD scaffold complex. While the interaction is real, GO:0005515 (protein binding) is uninformative. A more specific term such as GO:0051787 (misfolded protein binding) would capture the functional context, though the direct interaction with OS-9 is more of a scaffold co-complex interaction. The term could be modified to misfolded protein binding to reflect ERLEC1 function, but since the with/from is OS-9 (a co-complex partner, not a misfolded substrate), the annotation as stated is simply documenting a physical interaction.
Reason: GO:0005515 (protein binding) is uninformative per curation guidelines. ERLEC1 binds misfolded glycoproteins as a cargo receptor. The more informative term is GO:0051787 (misfolded protein binding), which captures ERLEC1 core molecular function of recognizing misfolded glycoprotein substrates for ERAD.
Proposed replacements:
misfolded protein binding
Supporting Evidence:
PMID:18502753
this large ER quality control scaffold complex, containing ER lectins, a chaperone, and a ubiquitin ligase, provides a platform for the recognition and sorting of misfolded glycoproteins as well as nonglycosylated proteins prior to retrotranslocation into the cytoplasm for degradation
|
|
GO:0005515
protein binding
|
IDA
PMID:16531414 The MRH protein Erlectin is a member of the endoplasmic reti... |
MODIFY |
Summary: IDA annotation for protein binding based on Cruciat et al. (PMID:16531414). This paper identified Erlectin as a protein that interacts with Kremen2 (KREMEN2), a coreceptor for Dickkopf1 in Wnt signaling. The interaction with Kremen2 is glycosylation-dependent (abolished by Kremen2 deglycosylation) and requires the second MRH domain of Erlectin (G379S mutation abolishes binding). Overexpression of Erlectin inhibited transport of Krm2 to the cell surface. This interaction reflects ERLEC1 lectin activity in glycoprotein quality control. GO:0005515 is uninformative; the functional activity is better captured by misfolded protein binding or N-glycan recognition.
Reason: GO:0005515 (protein binding) is uninformative per curation guidelines. The interaction with Kremen2 via N-glycan recognition represents ERLEC1 lectin function in the ER. The more informative term is GO:0051787 (misfolded protein binding), reflecting ERLEC1 role in recognizing glycoproteins for ER quality control.
Proposed replacements:
misfolded protein binding
Supporting Evidence:
PMID:16531414
Erlectin functions in N-glycan recognition in the endoplasmic reticulum, suggesting that it may regulate glycoprotein traffic
PMID:16531414
It contains two MRH domains, of which one is essential for Krm2 binding, and this interaction is abolished by Krm2 deglycosylation
|
|
GO:0005515
protein binding
|
IPI
PMID:18264092 OS-9 and GRP94 deliver mutant alpha1-antitrypsin to the Hrd1... |
MODIFY |
Summary: IPI annotation for protein binding based on Christianson et al. (PMID:18264092), with multiple interacting partners (UniProtKB:P11021 HSPA5/BiP, UniProtKB:Q86TM6 SYVN1/HRD1, UniProtKB:Q9UBV2 SEL1L). This paper showed that XTP3-B binds to ERAD substrates and through SEL1L to HRD1. The MRH domains are required for interaction with SEL1L but not with substrate. XTP3-B and OS-9 are components of distinct, partially redundant quality control surveillance pathways. GO:0005515 is uninformative; ERLEC1 interactions with SEL1L and HRD1 reflect its role as a substrate adaptor for the ERAD ubiquitin ligase complex.
Reason: GO:0005515 (protein binding) is uninformative per curation guidelines. The interactions documented here are functionally significant: ERLEC1 binding to SEL1L and HRD1 via its MRH domains reflects its role as a substrate adaptor that bridges misfolded glycoproteins to the E3 ubiquitin ligase complex. The most informative molecular function term would be GO:0051787 (misfolded protein binding), capturing ERLEC1 core activity of recognizing misfolded substrates.
Proposed replacements:
misfolded protein binding
Supporting Evidence:
PMID:18264092
OS-9 and XTP3-B/Erlectin are ER-resident glycoproteins that bind to ERAD substrates and, through the SEL1L adaptor, to the ER-membrane-embedded ubiquitin ligase Hrd1
PMID:18264092
Both proteins contain conserved mannose 6-phosphate receptor homology (MRH) domains, which are required for interaction with SEL1L, but not with substrate
|
|
GO:0005788
endoplasmic reticulum lumen
|
IDA
PMID:16531414 The MRH protein Erlectin is a member of the endoplasmic reti... |
ACCEPT |
Summary: IDA annotation for ER lumen localization based on Cruciat et al. (PMID:16531414). This paper demonstrated by immunofluorescence and mass spectrometry that Erlectin is a luminal resident protein of the endoplasmic reticulum. ERLEC1 has a signal peptide (aa 1-33) and lacks a transmembrane domain, consistent with a soluble ER lumen protein.
Reason: ER lumen localization is a well-established core feature of ERLEC1, directly demonstrated by Cruciat et al. The IDA evidence is strong and consistent with the protein sequence (signal peptide, no TM domain) and with other experimental studies.
Supporting Evidence:
PMID:16531414
Like other members of the MRH family, Erlectin is a luminal resident protein of the endoplasmic reticulum
|
|
GO:0005788
endoplasmic reticulum lumen
|
IDA
PMID:18264092 OS-9 and GRP94 deliver mutant alpha1-antitrypsin to the Hrd1... |
ACCEPT |
Summary: IDA annotation for ER lumen localization based on Christianson et al. (PMID:18264092). This paper confirmed that XTP3-B/Erlectin is an ER-resident glycoprotein, consistent with ER lumen localization established by Cruciat et al. (PMID:16531414) and Hosokawa et al. (PMID:18502753).
Reason: Independent experimental confirmation of ER lumen localization by a second research group. Consistent with all other evidence.
Supporting Evidence:
PMID:18264092
OS-9 and XTP3-B/Erlectin are ER-resident glycoproteins that bind to ERAD substrates and, through the SEL1L adaptor, to the ER-membrane-embedded ubiquitin ligase Hrd1
|
|
GO:0005515
protein binding
|
IPI
PMID:16531414 The MRH protein Erlectin is a member of the endoplasmic reti... |
MODIFY |
Summary: IPI annotation for protein binding based on Cruciat et al. (PMID:16531414), with UniProtKB:Q8K1S7 (mouse Kremen2) as the interacting partner. This paper identified Erlectin in a proteomic approach as a protein that interacts with Kremen2. The interaction is glycosylation-dependent and requires the MRH domain of Erlectin. GO:0005515 is uninformative; this interaction reflects ERLEC1 lectin activity in N-glycan recognition and glycoprotein quality control.
Reason: GO:0005515 (protein binding) is uninformative per curation guidelines. The interaction with glycosylated Kremen2 via the MRH domain reflects ERLEC1 lectin function. The more informative term is GO:0051787 (misfolded protein binding), as ERLEC1 recognizes glycoproteins in the context of ER quality control.
Proposed replacements:
misfolded protein binding
Supporting Evidence:
PMID:16531414
It contains two MRH domains, of which one is essential for Krm2 binding, and this interaction is abolished by Krm2 deglycosylation
PMID:16531414
The overexpression of Erlectin inhibits transport of Krm2 to the cell surface
|
|
GO:0051787
misfolded protein binding
|
IDA
PMID:18264092 OS-9 and GRP94 deliver mutant alpha1-antitrypsin to the Hrd1... |
NEW |
Summary: NEW annotation proposed for GO:0051787 (misfolded protein binding). Multiple studies demonstrate that ERLEC1/XTP3-B binds to misfolded glycoproteins in the ER. Christianson et al. (PMID:18264092) showed that XTP3-B binds to ERAD substrates (mutant alpha1-antitrypsin NHK). Hosokawa et al. (PMID:18502753) showed that hXTP3-B forms a scaffold complex for recognition and sorting of misfolded glycoproteins and nonglycosylated proteins. Groisman et al. (PMID:21062743) demonstrated that substrate association with XTP3-B depends on mannose trimming. This term is more informative than the generic GO:0005515 (protein binding) annotations currently present and accurately captures ERLEC1 core molecular function as a lectin that recognizes misfolded glycoprotein substrates for ERAD.
Reason: GO:0051787 (misfolded protein binding) is the most informative molecular function term for ERLEC1. It replaces the uninformative GO:0005515 (protein binding) annotations and provides the correct replacement for the obsolescent GO:0051082 (unfolded protein binding). ERLEC1 specifically binds misfolded glycoproteins (not simply unfolded polypeptides) as a cargo receptor for ERAD.
Supporting Evidence:
PMID:18264092
OS-9 and XTP3-B/Erlectin are ER-resident glycoproteins that bind to ERAD substrates and, through the SEL1L adaptor, to the ER-membrane-embedded ubiquitin ligase Hrd1
PMID:18502753
this large ER quality control scaffold complex, containing ER lectins, a chaperone, and a ubiquitin ligase, provides a platform for the recognition and sorting of misfolded glycoproteins as well as nonglycosylated proteins prior to retrotranslocation into the cytoplasm for degradation
PMID:21062743
substrate association with XTP3-B and with the E3 ubiquitin ligases HRD1 and SCF(Fbs2) was inhibited
|
|
GO:0097466
ubiquitin-dependent glycoprotein ERAD pathway
|
TAS
PMID:21062743 Mannose trimming is required for delivery of a glycoprotein ... |
NEW |
Summary: NEW annotation proposed for GO:0097466 (ubiquitin-dependent glycoprotein ERAD pathway). This term is more specific than GO:0036503 (ERAD pathway) and captures the fact that ERLEC1 specifically functions in the glycoprotein-specific branch of ERAD. Groisman et al. (PMID:21062743) showed that mannose trimming of N-glycans is required for substrate delivery from EDEM1 to XTP3-B, establishing ERLEC1 as a lectin that acts specifically in glycoprotein ERAD. The broader GO:0036503 (ERAD pathway) annotation should be retained as well, since Hosokawa et al. (PMID:18502753) showed that the long isoform also affects ERAD of the non-glycosylated NHK-QQQ substrate.
Reason: GO:0097466 is a more specific child term of GO:0036503 that precisely captures ERLEC1 role in the glycoprotein-specific branch of ERAD, where it recognizes trimmed N-glycans on misfolded substrates. This provides higher annotation specificity while the broader ERAD pathway term is retained for the non-glycoprotein ERAD role.
Supporting Evidence:
PMID:21062743
Our results suggest that mannose trimming enables delivery of a substrate glycoprotein from EDEM1 to late ERAD steps through association with XTP3-B
PMID:21062743
the mannosidase inhibitor kifunensine or ERManI knockdown do not affect binding of an ERAD substrate glycoprotein to EDEM1. In contrast, substrate association with XTP3-B and with the E3 ubiquitin ligases HRD1 and SCF(Fbs2) was inhibited
|
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-02-20T14:57:14.507946'
end_time: '2026-02-20T15:09:19.495095'
duration_seconds: 724.99
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: ERLEC1
gene_symbol: ERLEC1
uniprot_accession: Q96DZ1
protein_description: 'RecName: Full=Endoplasmic reticulum lectin 1; AltName: Full=ER
lectin; Short=Erlectin; AltName: Full=XTP3-transactivated gene B protein; Flags:
Precursor;'
gene_info: Name=ERLEC1; Synonyms=C2orf30, XTP3TPB; ORFNames=UNQ1878/PRO4321;
organism_full: Homo sapiens (Human).
protein_family: Not specified in UniProt
protein_domains: Man6P_isomerase_rcpt-bd_dom_sf. (IPR009011); MRH_dom. (IPR044865);
OS-9-like. (IPR045149); OS9-like_dom. (IPR012913); PRKCSH (PF07915)
provider_config:
timeout: 600
max_retries: 3
parameters:
allowed_domains: []
temperature: 0.1
citation_count: 29
BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.
DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'ERLEC1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information
Please provide a comprehensive research report on the gene ERLEC1 (gene ID: ERLEC1, UniProt: Q96DZ1) in human.
The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.
BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.
DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'ERLEC1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information
Please provide a comprehensive research report on the gene ERLEC1 (gene ID: ERLEC1, UniProt: Q96DZ1) in human.
The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
Title: Functional annotation research report β Human ERLEC1 (UniProt Q96DZ1; ER lectin 1 / Erlectin / XTP3TPB / XTP3B)
Target verification (gene/protein identity)
ERLEC1 (UniProt Q96DZ1) corresponds to the ER-resident lectin historically named XTP3-B / erlectin, a ~483 amino acid protein containing two mannose-6-phosphate receptor homology (MRH) domains implicated in N-glycan binding and ER protein quality control. Foundational experimental characterization described erlectin as an ER luminal resident protein that colocalizes with ER markers in mammalian cells and contains two MRH domains (often denoted D1/D2). (cruciat2006themrhprotein; publication date May 2006; URL https://doi.org/10.1074/jbc.m511872200) (cruciat2006themrhprotein pages 2-3)
Key concepts and definitions (current understanding)
2.1 ER quality control and ER-associated degradation (ERAD)
ERAD is a proteostasis pathway that recognizes terminally misfolded proteins in the endoplasmic reticulum (ER) lumen or membrane and targets them for retrotranslocation to the cytosol, ubiquitination, and proteasomal degradation. In mammals, a central ERAD branch is organized around the SEL1LβHRD1 (SYVN1) complex (βdisloconβ), which recruits luminal substrate-recognition factors, including lectins that decode glycan-based degradation signals on N-glycoproteins. (hosokawa2010theroleof; publication date Jun 2010; URL https://doi.org/10.1093/glycob/cwq013) (hosokawa2010theroleof pages 1-2)
2.2 MRH domains and glycan decoding in ERAD
MRH domains are carbohydrate-recognition modules found in several secretory-pathway lectins; in ERAD-related lectins (including OS9 and ERLEC1/XTP3B), MRH-mediated binding can recognize specific high-mannose N-glycan features that emerge during glycan processing/demannosylation of unproductively folding proteins. (hosokawa2010theroleof; publication date Jun 2010; URL https://doi.org/10.1093/glycob/cwq013) (hosokawa2010theroleof pages 1-2)
A commonly cited schematic places signal sequence and MRH domains in the luminal region of XTP3-B (human long vs short isoforms), consistent with an ER luminal lectin role. (hosokawa2010theroleof; Jun 2010; URL https://doi.org/10.1093/glycob/cwq013) (hosokawa2010theroleof media 808f4af7)
3.2 Domain architecture
ERLEC1/XTP3-B contains two MRH domains. Early work annotated and experimentally used this domain structure to analyze glycan-dependent binding to glycoproteins. (cruciat2006themrhprotein; May 2006; URL https://doi.org/10.1074/jbc.m511872200) (cruciat2006themrhprotein pages 2-3)
A review of MRH lectins in ERAD presents a domain schematic for human XTP3-B with signal sequence and two luminal MRH domains (long and short splice variants). (hosokawa2010theroleof; Jun 2010; URL https://doi.org/10.1093/glycob/cwq013) (hosokawa2010theroleof media 808f4af7)
3.3 Lectin activity and N-glycan binding specificity
Multiple primary studies support that the C-terminal MRH domain (MRH2) mediates ERLEC1 glycan binding.
β’ Man5-type recognition motif and glycan dependence in cell binding: ERLEC1/XTP3-B binding to Lec1 cell glycans depended on the C-terminal MRH domain and was abolished by Endo H treatment, supporting high-mannose N-glycan dependence. The study further implicated a terminal ManΞ±1,6Man motif (within Man5GlcNAc2 context) in recognition and demonstrated statistically significant Endo H effects (reported p < 0.001 in binding assays). (Yamaguchi et al., Glycobiology; publication date Nov 2010; URL https://doi.org/10.1093/glycob/cwp182) (yamaguchi2010humanxtp3bbinds pages 1-2)
β’ M9 (Man9GlcNAc2) binding in vitro and in vivo: Using frontal affinity chromatography and in vitro binding assays, ERLEC1/XTP3-Bβs C-terminal MRH domain showed specific binding to Man9GlcNAc2 (M9), whereas the N-terminal MRH domain did not show binding under the tested conditions. (Fujimori et al., FEBS Journal; publication date Mar 2013; URL https://doi.org/10.1111/febs.12157) (fujimori2013endoplasmicreticulumlectin pages 2-4, fujimori2013endoplasmicreticulumlectin pages 1-2)
β’ Connection to demannosylation signals recognized by ER lectins: A mechanistic genetic study framed glycoprotein ERAD as depending on lectin decoding of progressively demannosylated high-mannose glycans (Man5β7GlcNAc2) exposing a terminal Ξ±1,6-linked mannose, and positioned XTP3B/ERLEC1 as one of the lectins participating in this decoding. (van der Goot et al., Molecular Cell; publication date May 2018; URL https://doi.org/10.1016/j.molcel.2018.03.026) (goot2018redundantandantagonistic pages 1-3)
These findings indicate ERLEC1 is a lectin rather than an enzyme; its primary biochemical βsubstrate specificityβ is for defined high-mannose N-glycan features (Man5/Man9 and, in ERAD contexts, demannosylated high-mannose signals). (fujimori2013endoplasmicreticulumlectin pages 2-4, goot2018redundantandantagonistic pages 1-3, yamaguchi2010humanxtp3bbinds pages 1-2)
3.4 Proteinβprotein interactions and ERAD complex membership
3.4.1 Association with SEL1LβHRD1 ERAD machinery
ERLEC1/XTP3-B associates with the HRD1βSEL1L ubiquitin ligase complex, consistent with being a stable component of a large ERAD complex. Co-fractionation and interaction evidence indicates ERLEC1 connects luminal recognition to the membrane ubiquitination/retrotranslocation machinery. (Fujimori et al., FEBS Journal; Mar 2013; URL https://doi.org/10.1111/febs.12157) (fujimori2013endoplasmicreticulumlectin pages 2-4)
A review schematic of mammalian ERAD explicitly depicts OS-9 and XTP3-B associating with the SEL1LβHRD1 complex in the pathway that routes misfolded glycoproteins toward degradation. (hosokawa2010theroleof; Jun 2010; URL https://doi.org/10.1093/glycob/cwq013) (hosokawa2010theroleof media bdd75ee9)
3.4.2 Stabilization by SEL1L
SEL1L appears to stabilize ERLEC1 protein. In SEL1L depletion experiments, ERLEC1/XTP3-B displayed accelerated degradation in a cycloheximide chase (approximately 40% loss over 10 hours, with unchanged mRNA), consistent with proteasomal turnover when not assembled into the complex. (Fujimori et al., FEBS Journal; Mar 2013; URL https://doi.org/10.1111/febs.12157) (fujimori2013endoplasmicreticulumlectin pages 2-4)
3.4.3 Interactions preserved in SEL1L hypomorphic variant models (2024)
In a Nature Communications 2024 study dissecting SEL1LβHRD1 complex formation, ERLEC1 is listed among SEL1L-interacting components (βincluding OS9 and ERLEC1β), and a SEL1L hypomorphic variant (SEL1LS658P) was reported to attenuate SEL1LβHRD1 interaction while having no detectable effect on SEL1Lβlectin interactions with OS9/ERLEC1. Quantitatively, the SEL1LβHRD1 interaction was reduced by ~5-fold in knock-in livers; SEL1L and HRD1 levels were reduced by 20% and 60% in KI cerebellum, and by 20% and 30% in KI HEK293T cells (relative to WT), respectively. (Lin et al., Nature Communications; publication date Feb 2024; URL https://doi.org/10.1038/s41467-024-45633-0) (lin2024sel1lhrd1interactionis pages 6-7)
3.4.4 Expert synthesis: ERLEC1 as a luminal βbinder/escortβ to SEL1LβHRD1
A 2024 JCI expert commentary summarized ERLEC1/XTP3B (along with OS9 and EDEM1) as luminal factors that bind misfolded proteins in the ER lumen and bring them to SEL1L/SEL1LβHRD1 for ubiquitination and degradation, reflecting a consensus pathway model in which lectins act upstream of the dislocon. (Umphred-Wilson & Adoro, J Clin Invest; publication date Jan 2024; URL https://doi.org/10.1172/jci175448) (umphredwilson2024hypomorphichumansel1l pages 1-2)
Complementary evidence showed ERLEC1 binds an ERAD substrate (Ξ±1-antitrypsin nullHong Kong) via the C-terminal MRH domain in a glycan-dependent manner. (Yamaguchi et al., Glycobiology; Nov 2010; URL https://doi.org/10.1093/glycob/cwp182) (yamaguchi2010humanxtp3bbinds pages 1-1, yamaguchi2010humanxtp3bbinds pages 1-2)
4.2 Redundant and antagonistic roles with OS9 (triage of glycan vs non-glycan degrons)
A genetic deletion study of the two major metazoan Yos9 orthologs (OS9 and XTP3B/ERLEC1) concluded:
β’ OS9 and XTP3B redundantly promote glycoprotein degradation and stabilize the SEL1L/HRD1 complex.
β’ XTP3B strongly inhibits degradation of non-glycosylated substrates, and OS9 antagonizes this inhibition.
β’ The relative abundance of OS9 vs XTP3B and the distribution of glycan and non-glycan degrons within the same substrate influence ERAD βfidelity and processivity,β shaping protein fate in the early secretory pathway.
(van der Goot et al., Molecular Cell; May 2018; URL https://doi.org/10.1016/j.molcel.2018.03.026) (goot2018redundantandantagonistic pages 1-3)
These findings reconcile apparently conflicting observations (ERLEC1 inhibiting ERAD for some substrates) by supporting a model in which ERLEC1 can both facilitate glycoprotein ERAD (with OS9) and restrain degradation of certain proteins (especially non-glycosylated substrates and specific glycoprotein contexts), thereby tuning triage rather than acting as a simple βon/offβ ERAD factor. (goot2018redundantandantagonistic pages 1-3, fujimori2013endoplasmicreticulumlectin pages 1-2)
5.2 Crosstalk with ER stress (UPR) as a functional context
Because ERAD is a major ER proteostasis pathway, ERLEC1 function is often discussed in the context of ER stress/unfolded protein response (UPR). In multiple myeloma, experimental disruption of ERAD genes induces BiP (an ER stress marker), illustrating that perturbing ERAD increases ER stress in secretory-lineage cancers (see Section 6.1). (de Matos Simoes et al., Nature Cancer; May 2023; URL https://doi.org/10.1038/s43018-023-00550-x) (simoes2023genomescalefunctionalgenomics pages 9-10)
In the same work, the authors contextualize ERAD as a biological vulnerability in MM due to proteostatic stress from immunoglobulin production and experimentally validate ERAD gene knockouts (e.g., UBE2J1, SYVN1, HERPUD1) as affecting MM viability and ER stress markers. Although ERLEC1 is not individually validated in the excerpted sections, it is grouped within ERAD-related dependencies enriched in MM. (de Matos Simoes et al., Nature Cancer; May 2023; URL https://doi.org/10.1038/s43018-023-00550-x) (simoes2023genomescalefunctionalgenomics pages 9-10)
6.2 ERAD machinery in human disease: SEL1L/HRD1 variants (JCI 2024) and mechanistic definition of ERAD complex assembly (Nat Comms 2024)
Mechanistic work in 2024 emphasized that proper SEL1LβHRD1 interaction is required to form a functional HRD1 ERAD complex and documented that SEL1Lβlectin interactions with OS9/ERLEC1 are preserved despite compromised SEL1LβHRD1 binding in a hypomorphic variant model. (Lin et al., Nature Communications; Feb 2024; URL https://doi.org/10.1038/s41467-024-45633-0) (lin2024sel1lhrd1interactionis pages 6-7)
An authoritative 2024 JCI commentary framed ERLEC1/XTP3B as part of the luminal recognition/escort layer (with OS9 and EDEM1) that brings misfolded proteins to SEL1LβHRD1 for degradation, highlighting expert consensus on ERLEC1βs pathway role as ERAD biology becomes clinically relevant through pathogenic SEL1L/HRD1 variants. (Umphred-Wilson & Adoro, J Clin Invest; Jan 2024; URL https://doi.org/10.1172/jci175448) (umphredwilson2024hypomorphichumansel1l pages 1-2)
6.3 Disease-associated transcriptomic signatures featuring ERLEC1
6.3.1 Cancer-therapyβrelated cognitive impairment model (Brain Sciences 2023)
In a mouse model of cognitive impairment after cancer therapy, combined doxorubicin + hindlimb radiation (DOX-RT) altered brain gene expression and significantly increased Erlec1 expression. Table data reported Erlec1 mean normalized counts: control 497.7 (SEM 14.78), DOX 533.0 (SEM 8.97), RT 498.3 (SEM 8.82), DOX-RT 558.3 (SEM 8.70); overall ANOVA F = 7.634, p = 0.0014; with RT vs DOX-RT Tukey p = 0.0037 (n = 6 mice per group). (Demos-Davies et al., Brain Sciences; publication date Dec 2023; URL https://doi.org/10.3390/brainsci14010022) (demosdavies2023thedistantmolecular pages 8-10)
6.3.2 Interstitial cystitis host gene expression (Frontiers in Immunology 2024)
A study combining Mendelian randomization and bulk RNA-seq in interstitial cystitis reported ERLEC1 among upregulated βhub genesβ (along with CHAC2, ASB3, STAT5A, STAT3), suggesting ERLEC1 can appear in inflammatory/autoimmune-associated transcriptional programs. (Fu et al., Frontiers in Immunology; publication date Sep 2024; URL https://doi.org/10.3389/fimmu.2024.1395580) (fu2024gutmicrobiotaand pages 9-10)
7.2 Biomarker/omics signatures (expression panels)
ERLEC1 appears in differential-expression panels in diverse contexts (therapy-induced brain expression changes; inflammatory bladder disease hub-gene set), illustrating a real-world use pattern where ERLEC1 is a feature in transcriptomic signatures rather than a stand-alone biomarker with a mature clinical assay. (demosdavies2023thedistantmolecular pages 8-10, fu2024gutmicrobiotaand pages 9-10)
7.3 Mechanistic pathway modeling of ERAD
The ERAD model depicting ERLEC1 (XTP3-B) together with OS-9 interfacing with the SEL1LβHRD1 complex is used as a canonical representation for how N-glycan-binding lectins feed substrates into the ubiquitination/retrotranslocation machinery. (hosokawa2010theroleof; Jun 2010; URL https://doi.org/10.1093/glycob/cwq013) (hosokawa2010theroleof media bdd75ee9)
This supports a current model in which ERLEC1 is not merely a βdegradation receptor,β but a context-dependent triage factor controlling flux and selectivity in ER protein quality control, potentially balancing retention/refolding opportunities versus commitment to degradation. (goot2018redundantandantagonistic pages 1-3, fujimori2013endoplasmicreticulumlectin pages 1-2)
Key statistics and quantitative data highlights
β’ SEL1L stabilizes ERLEC1 protein: ~40% ERLEC1 loss over a 10-hour cycloheximide chase upon SEL1L depletion (protein turnover effect; mRNA unchanged). (Fujimori et al., FEBS J; Mar 2013; URL https://doi.org/10.1111/febs.12157) (fujimori2013endoplasmicreticulumlectin pages 2-4)
β’ Glycan-dependence statistical support: Endo H treatment significantly reduced XTP3-B binding in cell-binding assays (reported p < 0.001). (Yamaguchi et al., Glycobiology; Nov 2010; URL https://doi.org/10.1093/glycob/cwp182) (yamaguchi2010humanxtp3bbinds pages 1-2)
β’ ERLEC1 differential expression in a cancer-therapy brain model: Erlec1 ANOVA F = 7.634, p = 0.0014; control mean 497.7 vs DOX-RT mean 558.3 normalized counts (n = 6/group), with RT vs DOX-RT Tukey p = 0.0037. (Demos-Davies et al., Brain Sciences; Dec 2023; URL https://doi.org/10.3390/brainsci14010022) (demosdavies2023thedistantmolecular pages 8-10)
β’ ERAD complex perturbation with preserved ERLEC1 interaction: SEL1LβHRD1 interaction reduced ~5-fold in knock-in livers; SEL1L and HRD1 levels reduced by 20% and 60% in KI cerebellum (and by 20% and 30% in KI HEK293T cells). (Lin et al., Nat Comms; Feb 2024; URL https://doi.org/10.1038/s41467-024-45633-0) (lin2024sel1lhrd1interactionis pages 6-7)
Limitations and open questions for ERLEC1 functional annotation
Despite clear evidence for ER residency, MRH-domainβmediated glycan binding, and ERAD pathway involvement, several items remain incompletely resolved in the provided literature subset:
β’ High-resolution structural determinants of glycan binding and how ERLEC1βs Man5/Man9 binding relates quantitatively to ERAD βmannose-trimmedβ signals (e.g., Man5β7 terminal Ξ±1,6 mannose exposure) across diverse substrates.
β’ Substrate rules that determine whether ERLEC1 promotes ERAD, inhibits ERAD, or stabilizes the dislocon, especially in relation to OS9 abundance and the presence of non-glycan degrons.
These questions are directly motivated by the context-dependent behaviors reported across substrate-focused and genetic studies. (goot2018redundantandantagonistic pages 1-3, fujimori2013endoplasmicreticulumlectin pages 1-2)
Selected primary references (publication date; URL)
β’ Cruciat CM et al. J Biol Chem (May 2006). https://doi.org/10.1074/jbc.m511872200 (cruciat2006themrhprotein pages 2-3)
β’ Hosokawa N et al. Glycobiology (Jun 2010). https://doi.org/10.1093/glycob/cwq013 (hosokawa2010theroleof pages 1-2)
β’ Yamaguchi D et al. Glycobiology (Nov 2010). https://doi.org/10.1093/glycob/cwp182 (yamaguchi2010humanxtp3bbinds pages 1-2)
β’ Fujimori T et al. FEBS J (Mar 2013). https://doi.org/10.1111/febs.12157 (fujimori2013endoplasmicreticulumlectin pages 2-4)
β’ van der Goot AT et al. Mol Cell (May 2018). https://doi.org/10.1016/j.molcel.2018.03.026 (goot2018redundantandantagonistic pages 1-3)
Selected recent references (2023β2024 prioritized)
β’ de Matos Simoes R et al. Nature Cancer (May 2023). https://doi.org/10.1038/s43018-023-00550-x (simoes2023genomescalefunctionalgenomics pages 7-9)
β’ Demos-Davies KM et al. Brain Sciences (Dec 2023). https://doi.org/10.3390/brainsci14010022 (demosdavies2023thedistantmolecular pages 8-10)
β’ Lin LGL et al. Nature Communications (Feb 2024). https://doi.org/10.1038/s41467-024-45633-0 (lin2024sel1lhrd1interactionis pages 6-7)
β’ Umphred-Wilson K, Adoro S. J Clin Invest (Jan 2024). https://doi.org/10.1172/jci175448 (umphredwilson2024hypomorphichumansel1l pages 1-2)
β’ Fu C et al. Frontiers in Immunology (Sep 2024). https://doi.org/10.3389/fimmu.2024.1395580 (fu2024gutmicrobiotaand pages 9-10)
References
(cruciat2006themrhprotein pages 2-3): Cristina-Maria Cruciat, Christine Hassler, and Christof Niehrs. The mrh protein erlectin is a member of the endoplasmic reticulum synexpression group and functions in n-glycan recognition*. Journal of Biological Chemistry, 281:12986-12993, May 2006. URL: https://doi.org/10.1074/jbc.m511872200, doi:10.1074/jbc.m511872200. This article has 47 citations and is from a domain leading peer-reviewed journal.
(hosokawa2010theroleof pages 1-2): N. Hosokawa, Y. Kamiya, and Koichi Kato. The role of mrh domain-containing lectins in erad. Glycobiology, 20 6:651-60, Jun 2010. URL: https://doi.org/10.1093/glycob/cwq013, doi:10.1093/glycob/cwq013. This article has 89 citations and is from a peer-reviewed journal.
(hosokawa2010theroleof media 808f4af7): N. Hosokawa, Y. Kamiya, and Koichi Kato. The role of mrh domain-containing lectins in erad. Glycobiology, 20 6:651-60, Jun 2010. URL: https://doi.org/10.1093/glycob/cwq013, doi:10.1093/glycob/cwq013. This article has 89 citations and is from a peer-reviewed journal.
(yamaguchi2010humanxtp3bbinds pages 1-2): D. Yamaguchi, D. Hu, N. Matsumoto, and K. Yamamoto. Human xtp3-b binds to 1-antitrypsin variant nullhong kong via the c-terminal mrh domain in a glycan-dependent manner. Glycobiology, 20:348-355, Nov 2010. URL: https://doi.org/10.1093/glycob/cwp182, doi:10.1093/glycob/cwp182. This article has 61 citations and is from a peer-reviewed journal.
(fujimori2013endoplasmicreticulumlectin pages 2-4): Tsutomu Fujimori, Yukiko Kamiya, Kazuhiro Nagata, Koichi Kato, and Nobuko Hosokawa. Endoplasmic reticulum lectin xtp3βb inhibits endoplasmic reticulumβassociated degradation of a misfolded Ξ±1βantitrypsin variant. The FEBS Journal, 280:1563-1575, Mar 2013. URL: https://doi.org/10.1111/febs.12157, doi:10.1111/febs.12157. This article has 50 citations.
(fujimori2013endoplasmicreticulumlectin pages 1-2): Tsutomu Fujimori, Yukiko Kamiya, Kazuhiro Nagata, Koichi Kato, and Nobuko Hosokawa. Endoplasmic reticulum lectin xtp3βb inhibits endoplasmic reticulumβassociated degradation of a misfolded Ξ±1βantitrypsin variant. The FEBS Journal, 280:1563-1575, Mar 2013. URL: https://doi.org/10.1111/febs.12157, doi:10.1111/febs.12157. This article has 50 citations.
(goot2018redundantandantagonistic pages 1-3): Annemieke T. van der Goot, Margaret M.P. Pearce, Dara E. Leto, Thomas A. Shaler, and Ron R. Kopito. Redundant and antagonistic roles of xtp3b and os9 in decoding glycan and non-glycan degrons in er-associated degradation. Molecular cell, 70 3:516-530.e6, May 2018. URL: https://doi.org/10.1016/j.molcel.2018.03.026, doi:10.1016/j.molcel.2018.03.026. This article has 71 citations and is from a highest quality peer-reviewed journal.
(hosokawa2010theroleof media bdd75ee9): N. Hosokawa, Y. Kamiya, and Koichi Kato. The role of mrh domain-containing lectins in erad. Glycobiology, 20 6:651-60, Jun 2010. URL: https://doi.org/10.1093/glycob/cwq013, doi:10.1093/glycob/cwq013. This article has 89 citations and is from a peer-reviewed journal.
(lin2024sel1lhrd1interactionis pages 6-7): Liangguang Leo Lin, Huilun Helen Wang, Brent Pederson, Xiaoqiong Wei, Mauricio Torres, You Lu, Zexin Jason Li, Xiaodan Liu, Hancheng Mao, Hui Wang, Linyao Elina Zhou, Zhen Zhao, Shengyi Sun, and Ling Qi. Sel1l-hrd1 interaction is required to form a functional hrd1 erad complex. Nature Communications, Feb 2024. URL: https://doi.org/10.1038/s41467-024-45633-0, doi:10.1038/s41467-024-45633-0. This article has 36 citations and is from a highest quality peer-reviewed journal.
(umphredwilson2024hypomorphichumansel1l pages 1-2): Katharine Umphred-Wilson and Stanley Adoro. Hypomorphic human sel1l and hrd1 variants uncouple multilayered er-associated degradation machinery. The Journal of Clinical Investigation, Jan 2024. URL: https://doi.org/10.1172/jci175448, doi:10.1172/jci175448. This article has 4 citations.
(yamaguchi2010humanxtp3bbinds pages 1-1): D. Yamaguchi, D. Hu, N. Matsumoto, and K. Yamamoto. Human xtp3-b binds to 1-antitrypsin variant nullhong kong via the c-terminal mrh domain in a glycan-dependent manner. Glycobiology, 20:348-355, Nov 2010. URL: https://doi.org/10.1093/glycob/cwp182, doi:10.1093/glycob/cwp182. This article has 61 citations and is from a peer-reviewed journal.
(simoes2023genomescalefunctionalgenomics pages 9-10): Ricardo de Matos Simoes, Ryosuke Shirasaki, Sondra L. Downey-Kopyscinski, Geoffrey M. Matthews, Benjamin G. Barwick, Vikas A. Gupta, DaphnΓ© DupΓ©rΓ©-Richer, Shizuka Yamano, Yiguo Hu, Michal Sheffer, Eugen Dhimolea, Olga Dashevsky, Sara Gandolfi, Kazuya Ishiguro, Robin M. Meyers, Jordan G. Bryan, Neekesh V. Dharia, Paul J. Hengeveld, Johanna B. BrΓΌggenthies, Huihui Tang, Andrew J. Aguirre, Quinlan L. Sievers, Benjamin L. Ebert, Brian J. Glassner, Christopher J. Ott, James E. Bradner, Nicholas P. Kwiatkowski, Daniel Auclair, Joan Levy, Jonathan J. Keats, Richard W. J. Groen, Nathanael S. Gray, Aedin C. Culhane, James M. McFarland, Joshua M. Dempster, Jonathan D. Licht, Lawrence H. Boise, William C. Hahn, Francisca Vazquez, Aviad Tsherniak, and Constantine S. Mitsiades. Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias. Nature Cancer, 4:754-773, May 2023. URL: https://doi.org/10.1038/s43018-023-00550-x, doi:10.1038/s43018-023-00550-x. This article has 38 citations and is from a highest quality peer-reviewed journal.
(simoes2023genomescalefunctionalgenomics pages 7-9): Ricardo de Matos Simoes, Ryosuke Shirasaki, Sondra L. Downey-Kopyscinski, Geoffrey M. Matthews, Benjamin G. Barwick, Vikas A. Gupta, DaphnΓ© DupΓ©rΓ©-Richer, Shizuka Yamano, Yiguo Hu, Michal Sheffer, Eugen Dhimolea, Olga Dashevsky, Sara Gandolfi, Kazuya Ishiguro, Robin M. Meyers, Jordan G. Bryan, Neekesh V. Dharia, Paul J. Hengeveld, Johanna B. BrΓΌggenthies, Huihui Tang, Andrew J. Aguirre, Quinlan L. Sievers, Benjamin L. Ebert, Brian J. Glassner, Christopher J. Ott, James E. Bradner, Nicholas P. Kwiatkowski, Daniel Auclair, Joan Levy, Jonathan J. Keats, Richard W. J. Groen, Nathanael S. Gray, Aedin C. Culhane, James M. McFarland, Joshua M. Dempster, Jonathan D. Licht, Lawrence H. Boise, William C. Hahn, Francisca Vazquez, Aviad Tsherniak, and Constantine S. Mitsiades. Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias. Nature Cancer, 4:754-773, May 2023. URL: https://doi.org/10.1038/s43018-023-00550-x, doi:10.1038/s43018-023-00550-x. This article has 38 citations and is from a highest quality peer-reviewed journal.
(demosdavies2023thedistantmolecular pages 8-10): Kimberly M. Demos-Davies, Jessica Lawrence, Clara Ferreira, and Davis Seelig. The distant molecular effects on the brain by cancer treatment. Brain Sciences, 14:22, Dec 2023. URL: https://doi.org/10.3390/brainsci14010022, doi:10.3390/brainsci14010022. This article has 2 citations.
(fu2024gutmicrobiotaand pages 9-10): Chaowei Fu, Yu Zhao, Xiang Zhou, Jing Lv, Shengkai Jin, Yuhua Zhou, Fengping Liu, and Ninghan Feng. Gut microbiota and interstitial cystitis: exploring the gut-bladder axis through mendelian randomization, biological annotation and bulk rna sequencing. Frontiers in Immunology, Sep 2024. URL: https://doi.org/10.3389/fimmu.2024.1395580, doi:10.3389/fimmu.2024.1395580. This article has 9 citations and is from a peer-reviewed journal.
id: Q96DZ1
gene_symbol: ERLEC1
product_type: PROTEIN
status: IN_PROGRESS
taxon:
id: NCBITaxon:9606
label: Homo sapiens
description: >-
ERLEC1 (also known as XTP3-B or Erlectin) is an ER-resident lectin containing
two mannose 6-phosphate receptor homology (MRH) domains. It functions as a
context-dependent triage factor in the endoplasmic reticulum-associated
degradation (ERAD) pathway, recognizing misfolded glycoproteins via their
trimmed N-glycan sugar moieties and delivering them to the HRD1-SEL1L ubiquitin
ligase complex for retrotranslocation and proteasomal degradation. The
C-terminal MRH domain (MRH2) mediates glycan binding with specificity for
Man9GlcNAc2 (M9) and Man5-type high-mannose N-glycans exposing a terminal
alpha-1,6-linked mannose motif (DOI:10.1093/glycob/cwp182,
DOI:10.1111/febs.12157). ERLEC1 forms a large ER quality control scaffold
complex together with OS-9, BiP (HSPA5), and the HRD1-SEL1L ubiquitin ligase.
The long isoform (hXTP3-B-long) associates with this scaffold and can retard
ERAD of both glycosylated and non-glycosylated substrates, while the short
isoform is excluded from scaffold formation. SEL1L stabilizes ERLEC1 protein;
SEL1L depletion causes accelerated ERLEC1 degradation (~40% loss over 10 hours
in cycloheximide chase) without change in mRNA levels (DOI:10.1111/febs.12157).
Genetic studies reveal that ERLEC1 and OS9 play redundant and antagonistic roles
in ERAD: both redundantly promote glycoprotein degradation and stabilize
SEL1L-HRD1, but ERLEC1 strongly inhibits degradation of non-glycosylated
substrates, with OS9 antagonizing this inhibition, thereby tuning ERAD substrate
selectivity (DOI:10.1016/j.molcel.2018.03.026). Mannose trimming by ER
mannosidase I is required for substrate delivery from EDEM1 to XTP3-B,
consistent with its role as a lectin-based ERAD cargo receptor rather than a
chaperone.
alternative_products:
- name: 1 (hXTP3B-long)
id: Q96DZ1-1
- name: 2 (hXTP3B-short)
id: Q96DZ1-2
sequence_note: VSP_015790
- name: '3'
id: Q96DZ1-3
sequence_note: VSP_047155
existing_annotations:
- term:
id: GO:0005788
label: endoplasmic reticulum lumen
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
IBA annotation placing ERLEC1 in the ER lumen, inferred from phylogenetic
analysis. This is strongly supported by multiple independent experimental
studies. Cruciat et al. (PMID:16531414) showed that Erlectin is a luminal
resident protein of the endoplasmic reticulum. Hosokawa et al.
(PMID:18502753) confirmed ER lumen localization. Christianson et al.
(PMID:18264092) also demonstrated ER lumen localization. UniProt annotates
subcellular location as ER lumen with experimental evidence. ERLEC1 has a
signal peptide (aa 1-33) and lacks a transmembrane domain, consistent with
a soluble ER lumen protein retained by the quality control machinery.
action: ACCEPT
reason: >-
ER lumen localization is a core feature of ERLEC1 function as an ERAD
cargo receptor. The IBA annotation is fully consistent with multiple
experimental (IDA) demonstrations of ER lumen localization.
supported_by:
- reference_id: PMID:16531414
supporting_text: >-
Like other members of the MRH family, Erlectin is a luminal resident
protein of the endoplasmic reticulum
- reference_id: PMID:18502753
supporting_text: >-
hXTP3-B long isoform associates with the HRD1-SEL1L membrane-anchored
ubiquitin ligase complex and BiP, forming a 27 S ER quality control
scaffold complex
- term:
id: GO:0030970
label: retrograde protein transport, ER to cytosol
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
IBA annotation for involvement in retrograde protein transport, ER to
cytosol, inferred from phylogenetic analysis including yeast Yos9p.
ERLEC1/XTP3-B is a key component of the ERAD pathway that delivers
misfolded glycoproteins to the HRD1-SEL1L ubiquitin ligase complex for
retrotranslocation and proteasomal degradation (PMID:18264092,
PMID:18502753). Hosokawa et al. (PMID:18502753) showed that ERLEC1 forms
a scaffold complex that provides a platform for recognition and sorting
of misfolded proteins prior to retrotranslocation into the cytoplasm.
Groisman et al. (PMID:21062743) demonstrated that mannose trimming is
required for substrate delivery from EDEM1 to XTP3-B and to late ERAD
steps. This term is appropriate as ERLEC1 participates in the process
that moves ER proteins to the cytosol for degradation.
action: ACCEPT
reason: >-
Retrograde protein transport ER to cytosol is a core process that ERLEC1
participates in as an ERAD cargo receptor. The IBA annotation is well
supported by experimental evidence from multiple groups showing ERLEC1
functions in delivering misfolded substrates to the retrotranslocation
machinery.
supported_by:
- reference_id: PMID:18502753
supporting_text: >-
this large ER quality control scaffold complex, containing ER lectins,
a chaperone, and a ubiquitin ligase, provides a platform for the
recognition and sorting of misfolded glycoproteins as well as
nonglycosylated proteins prior to retrotranslocation into the cytoplasm
for degradation
- reference_id: PMID:18264092
supporting_text: >-
OS-9 and XTP3-B/Erlectin are ER-resident glycoproteins that bind to
ERAD substrates and, through the SEL1L adaptor, to the
ER-membrane-embedded ubiquitin ligase Hrd1
- reference_id: PMID:21062743
supporting_text: >-
Our results suggest that mannose trimming enables delivery of a
substrate glycoprotein from EDEM1 to late ERAD steps through
association with XTP3-B
- term:
id: GO:0005783
label: endoplasmic reticulum
evidence_type: IEA
original_reference_id: GO_REF:0000117
review:
summary: >-
IEA annotation from ARBA machine learning placing ERLEC1 in the
endoplasmic reticulum. This is correct but less specific than
GO:0005788 (endoplasmic reticulum lumen), which is supported by
IDA evidence from multiple publications (PMID:16531414, PMID:18264092)
and IBA evidence. ERLEC1 is a soluble ER lumen protein, not a
membrane-associated protein, so the more specific ER lumen term is
more appropriate. However, as an IEA annotation, it is acceptable to
retain a broader term that is not incorrect.
action: ACCEPT
reason: >-
While GO:0005783 (endoplasmic reticulum) is less specific than the
experimentally supported GO:0005788 (ER lumen), it is not incorrect.
The IEA annotation is a broader but valid computational inference.
The more specific ER lumen localization is already captured by
separate IDA and IBA annotations.
- term:
id: GO:0005788
label: endoplasmic reticulum lumen
evidence_type: IEA
original_reference_id: GO_REF:0000044
review:
summary: >-
IEA annotation mapping ERLEC1 to the ER lumen based on
UniProtKB/Swiss-Prot subcellular location vocabulary. UniProt annotates
ERLEC1 subcellular location as "Endoplasmic reticulum lumen" with
experimental evidence from PMID:16531414 and PMID:18502753. This
computational mapping is fully consistent with the experimental data.
action: ACCEPT
reason: >-
The IEA mapping from UniProt subcellular location to GO:0005788 is
correct and consistent with experimental evidence. ERLEC1 ER lumen
localization is well established.
- term:
id: GO:0030968
label: endoplasmic reticulum unfolded protein response
evidence_type: IEA
original_reference_id: GO_REF:0000002
review:
summary: >-
IEA annotation from InterPro (IPR045149, OS-9-like domain) mapping to the
ER unfolded protein response. ERLEC1 is part of the ER quality control
machinery but its primary role is in ERAD, not the canonical unfolded
protein response (UPR) signaling pathway. The UPR is a transcriptional
signaling response involving IRE1, PERK, and ATF6 pathways that activates
gene expression to cope with ER stress. ERLEC1 does not participate in
UPR signaling; rather, it functions downstream as a cargo receptor in
ERAD, recognizing misfolded glycoproteins and delivering them to the
HRD1-SEL1L complex for retrotranslocation (PMID:18264092, PMID:18502753).
The ERAD pathway annotation (GO:0036503) is the more precise term.
action: MODIFY
reason: >-
GO:0030968 (ER unfolded protein response) refers to the UPR signaling
cascade, not to ERAD per se. ERLEC1 is not a UPR signaling component
but rather an ERAD cargo receptor. The correct biological process term
is GO:0036503 (ERAD pathway), which is already annotated separately.
This IEA annotation likely arises from an overly broad InterPro-to-GO
mapping for the OS-9-like domain family.
proposed_replacement_terms:
- id: GO:0036503
label: ERAD pathway
- term:
id: GO:0036503
label: ERAD pathway
evidence_type: IEA
original_reference_id: GO_REF:0000002
review:
summary: >-
IEA annotation from InterPro (IPR045149, OS-9-like) mapping to the ERAD
pathway. This is fully supported by extensive experimental evidence.
ERLEC1/XTP3-B is a central component of the ERAD pathway, functioning
as a lectin-based cargo receptor that recognizes misfolded glycoproteins
and delivers them to the HRD1-SEL1L ubiquitin ligase complex
(PMID:18264092, PMID:18502753, PMID:21062743). Groisman et al.
(PMID:21062743) specifically demonstrated that mannose trimming is
required for substrate delivery from EDEM1 to XTP3-B and to late ERAD
steps. Christianson et al. (PMID:18264092) showed that XTP3-B binds to
ERAD substrates and through SEL1L to HRD1, and is required for
degradation of mutant alpha1-antitrypsin.
action: ACCEPT
reason: >-
The ERAD pathway is the core biological process in which ERLEC1
participates. The IEA annotation is correct and well supported by
experimental evidence from multiple independent studies.
- term:
id: GO:0036503
label: ERAD pathway
evidence_type: TAS
original_reference_id: PMID:21062743
review:
summary: >-
TAS annotation for ERAD pathway involvement based on Groisman et al.
(PMID:21062743). This paper directly demonstrates that XTP3-B functions
in the ERAD pathway by showing that mannose trimming by ER mannosidase I
is required for substrate delivery from EDEM1 to XTP3-B, and that
inhibition of mannose trimming blocks substrate association with XTP3-B
and with E3 ubiquitin ligases HRD1 and SCF(Fbs2). This establishes
ERLEC1 as a lectin acting at a late step in the ERAD pathway, after
mannose trimming and before ubiquitination and retrotranslocation.
action: ACCEPT
reason: >-
ERAD pathway involvement is the core function of ERLEC1. The TAS
annotation is well supported by the cited reference, which directly
demonstrates ERLEC1 function in delivering substrates to late ERAD
steps in a mannose-trimming-dependent manner.
supported_by:
- reference_id: PMID:21062743
supporting_text: >-
Our results suggest that mannose trimming enables delivery of a
substrate glycoprotein from EDEM1 to late ERAD steps through
association with XTP3-B
- reference_id: PMID:21062743
supporting_text: >-
substrate association with XTP3-B and with the E3 ubiquitin ligases
HRD1 and SCF(Fbs2) was inhibited
- term:
id: GO:0051082
label: unfolded protein binding
evidence_type: IDA
original_reference_id: PMID:21062743
review:
summary: >-
GO:0051082 (unfolded protein binding) is being obsoleted (go-ontology#30962).
The suggested replacements are holdase chaperone activity or protein folding
chaperone (GO:0044183), neither of which applies to ERLEC1. ERLEC1/XTP3-B is
an ER lectin that recognizes misfolded glycoproteins via their trimmed N-glycan
moieties as part of the ERAD pathway (PMID:21062743, PMID:18502753). It is not
a chaperone. Groisman et al. (PMID:21062743) showed that mannose trimming by
ER mannosidase I is required for substrate delivery from EDEM1 to XTP3-B,
establishing ERLEC1 as a lectin-based cargo receptor rather than a protein that
directly binds unfolded polypeptide chains. Christianson et al. (PMID:18264092)
demonstrated that the MRH domains of XTP3-B are required for interaction with
SEL1L but not with substrate, and that XTP3-B and OS-9 are components of
quality control surveillance pathways that coordinate protein folding with
membrane dislocation and ubiquitin conjugation. Hosokawa et al. (PMID:18502753)
showed that hXTP3-B forms a scaffold with HRD1-SEL1L and BiP, and that the
long isoform retarded ERAD of both glycosylated (NHK) and non-glycosylated
(NHK-QQQ) substrates. While ERLEC1 does interact with misfolded proteins,
this interaction is in the context of ERAD substrate recognition and delivery
to the ubiquitin ligase complex, not chaperone-like unfolded protein binding.
The ERAD pathway involvement is already captured by GO:0036503.
action: REMOVE
reason: >-
GO:0051082 is being obsoleted. The replacement terms (holdase chaperone,
foldase chaperone) do not apply to ERLEC1, which is a lectin-based ERAD cargo
receptor, not a chaperone. ERLEC1 recognizes misfolded glycoproteins through
their N-glycan sugar moieties (requiring mannose trimming) and delivers them
to the HRD1-SEL1L ubiquitin ligase complex for degradation. This is substrate
recognition for ERAD targeting, not chaperone-like binding to unfolded
polypeptide chains. The relevant biological function is already captured by
the ERAD pathway annotation (GO:0036503) and retrograde protein transport
annotation (GO:0030970). Similar to SYVN1, ERLEC1 interacts with misfolded
proteins as part of the ERAD machinery, which does not constitute unfolded
protein binding in the chaperone sense.
additional_reference_ids:
- PMID:18502753
- PMID:18264092
- PMID:16531414
supported_by:
- reference_id: PMID:21062743
supporting_text: >-
Our results suggest that mannose trimming enables delivery of a
substrate glycoprotein from EDEM1 to late ERAD steps through
association with XTP3-B
- reference_id: PMID:21062743
supporting_text: >-
substrate association with XTP3-B and with the E3 ubiquitin ligases
HRD1 and SCF(Fbs2) was inhibited
- reference_id: PMID:18264092
supporting_text: >-
OS-9 and XTP3-B/Erlectin are ER-resident glycoproteins that bind to
ERAD substrates and, through the SEL1L adaptor, to the
ER-membrane-embedded ubiquitin ligase Hrd1
- reference_id: PMID:18264092
supporting_text: >-
Both proteins contain conserved mannose 6-phosphate receptor homology
(MRH) domains, which are required for interaction with SEL1L, but not
with substrate
- reference_id: PMID:18264092
supporting_text: >-
XTP3-B and OS-9 are components of distinct, partially redundant,
quality control surveillance pathways that coordinate protein folding
with membrane dislocation and ubiquitin conjugation in mammalian cells
- reference_id: PMID:18502753
supporting_text: >-
hXTP3-B long isoform associates with the HRD1-SEL1L membrane-anchored
ubiquitin ligase complex and BiP, forming a 27 S ER quality control
scaffold complex
- reference_id: PMID:18502753
supporting_text: >-
this large ER quality control scaffold complex, containing ER lectins,
a chaperone, and a ubiquitin ligase, provides a platform for the
recognition and sorting of misfolded glycoproteins as well as
nonglycosylated proteins prior to retrotranslocation into the cytoplasm
for degradation
- reference_id: PMID:16531414
supporting_text: >-
Erlectin functions in N-glycan recognition in the endoplasmic
reticulum, suggesting that it may regulate glycoprotein traffic
- term:
id: GO:1904153
label: negative regulation of retrograde protein transport, ER to cytosol
evidence_type: IMP
original_reference_id: PMID:25660456
review:
summary: >-
IMP annotation for negative regulation of retrograde protein transport
(ER to cytosol) based on Zhong et al. (PMID:25660456). This paper used
RNAi knockdown and a dislocation-reconstituted GFP (drGFP) assay to
assess the requirement of ERAD components for dislocation of NHK (null
Hong Kong variant of alpha1-antitrypsin). The study found that knockdown
of 7 of 21 ERAD components enhanced NHK dislocation. If ERLEC1 knockdown
enhanced dislocation, this would be consistent with a negative regulatory
role. However, this seemingly contradicts the established role of ERLEC1
as a facilitator of ERAD (delivering substrates to the ubiquitin ligase).
Hosokawa et al. (PMID:18502753) showed that overexpression of the long
isoform of hXTP3-B retarded ERAD of both NHK and NHK-QQQ, which is
consistent with a negative regulatory effect when in excess. This
paradoxical role may reflect that excess ERLEC1 sequesters substrates or
blocks the retrotranslocation channel. The annotation captures the
experimental observation but should be interpreted cautiously as possibly
reflecting an overexpression/dosage artifact rather than a normal
physiological function.
action: KEEP_AS_NON_CORE
reason: >-
The annotation captures a real experimental observation (IMP evidence)
but the negative regulation of retrotranslocation is likely not the
primary physiological role of ERLEC1. Its core function is as a cargo
receptor that facilitates ERAD. The negative regulatory effect may
reflect dosage-dependent or context-dependent modulation. Hosokawa et al.
(PMID:18502753) also observed that hXTP3-B overexpression retards ERAD,
consistent with a scaffolding role where excess cargo receptor can
sequester substrates away from the retrotranslocation machinery.
additional_reference_ids:
- PMID:18502753
supported_by:
- reference_id: PMID:25660456
supporting_text: >-
knockdown of 7 of the 21 components enhanced NHK dislocation
- reference_id: PMID:18502753
supporting_text: >-
both isoforms retard ERAD of the human alpha(1)-antitrypsin variant
null Hong Kong (NHK), a terminally misfolded glycoprotein
- reference_id: PMID:18502753
supporting_text: >-
The hXTP3-B long isoform strongly inhibited ERAD of NHK-QQQ, which
lacks all of the N-glycosylation sites of NHK
- term:
id: GO:0044322
label: endoplasmic reticulum quality control compartment
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5362412
review:
summary: >-
TAS annotation from Reactome (R-HSA-5362412: SYVN1 ubiquitinates Hh
C-terminal fragments) placing ERLEC1 in the ER quality control
compartment (ERQC). The ERQC is a pericentriolar ER-derived compartment
where ERAD machinery concentrates along with misfolded substrates.
Groisman et al. (PMID:21062743) showed that XTP3-B associates with ERAD
substrates and E3 ligases in a mannose-trimming-dependent manner,
consistent with localization to the ERQC. The Reactome entry describes
ERLEC1 as a lectin in the ERAD machinery that helps target Hedgehog
C-terminal fragments for degradation. This is a reasonable localization
annotation for ERLEC1 given its role in ERAD substrate recognition.
action: ACCEPT
reason: >-
ERQC localization is consistent with ERLEC1 function in ERAD. As a
cargo receptor that concentrates with ERAD machinery and substrates,
ERLEC1 localizes to this quality control compartment. Multiple
Reactome entries reference the same biological role; this is one of
many duplicate TAS annotations from different Reactome reactions.
supported_by:
- reference_id: PMID:21062743
supporting_text: >-
substrate association with XTP3-B and with the E3 ubiquitin ligases
HRD1 and SCF(Fbs2) was inhibited
- term:
id: GO:0044322
label: endoplasmic reticulum quality control compartment
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5362437
review:
summary: >-
TAS annotation from Reactome (R-HSA-5362437: C-terminal Hh fragments
are bound by lectins). This Reactome entry explicitly states that
depletion of OS9 and ERLEC1 abrogates degradation of Hh-C fragments,
and that they may target Hh-C to the retrotranslocation channel via
interaction with SEL1. ERQC localization is appropriate for ERLEC1
given its established role as an ERAD lectin cargo receptor.
action: ACCEPT
reason: >-
Duplicate ERQC localization annotation from a different Reactome
reaction. Same rationale as for R-HSA-5362412: ERLEC1 localizes to
the ERQC as part of its ERAD cargo receptor function.
- term:
id: GO:0044322
label: endoplasmic reticulum quality control compartment
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5362441
review:
summary: >-
TAS annotation from Reactome (R-HSA-5362441: C-terminal Hh fragments
are recruited to SEL1:SYVN1 at the ER membrane). ERLEC1 participates
in recruiting substrates to the SEL1L-SYVN1 complex at the ER membrane,
consistent with ERQC localization.
action: ACCEPT
reason: >-
Duplicate ERQC localization annotation from a different Reactome
reaction describing the same ERAD process for Hh fragments.
- term:
id: GO:0044322
label: endoplasmic reticulum quality control compartment
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5362450
review:
summary: >-
TAS annotation from Reactome (R-HSA-5362450: Hh processing variants
bind lectins). This entry describes how OS9 and ERLEC1 lectins are
required for degradation of Hh processing-defective variants via the
ERAD pathway, consistent with ERQC localization.
action: ACCEPT
reason: >-
Duplicate ERQC localization annotation from a different Reactome
reaction describing ERAD of Hedgehog processing variants.
- term:
id: GO:0044322
label: endoplasmic reticulum quality control compartment
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5362459
review:
summary: >-
TAS annotation from Reactome (R-HSA-5362459: VCP-catalyzed ATP
hydrolysis promotes the translocation of Hh-C into the cytosol).
ERLEC1 is part of the ERAD machinery that operates within the ERQC.
action: ACCEPT
reason: >-
Duplicate ERQC localization annotation from a Reactome reaction
describing the VCP-dependent retrotranslocation step for Hh-C
fragments in which ERLEC1 participates upstream.
- term:
id: GO:0044322
label: endoplasmic reticulum quality control compartment
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5387386
review:
summary: >-
TAS annotation from Reactome (R-HSA-5387386: Hh processing variants
are recruited to SEL1:SYVN at the ER membrane). ERLEC1 participates
in recruiting Hh processing variants to the ubiquitin ligase complex.
action: ACCEPT
reason: >-
Duplicate ERQC localization annotation from a Reactome reaction.
Same biological context as other Hh ERAD entries.
- term:
id: GO:0044322
label: endoplasmic reticulum quality control compartment
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5387389
review:
summary: >-
TAS annotation from Reactome (R-HSA-5387389: Hh processing variants
are translocated to the cytosol in a VCP-dependent manner). Part of
the Hh ERAD pathway in which ERLEC1 acts as cargo receptor.
action: ACCEPT
reason: >-
Duplicate ERQC localization annotation from a Reactome reaction
in the Hh ERAD pathway.
- term:
id: GO:0044322
label: endoplasmic reticulum quality control compartment
evidence_type: TAS
original_reference_id: Reactome:R-HSA-5483238
review:
summary: >-
TAS annotation from Reactome (R-HSA-5483238: Hh processing variants
are ubiquitinated). ERLEC1 functions upstream of the ubiquitination
step in ERAD, within the ERQC.
action: ACCEPT
reason: >-
Duplicate ERQC localization annotation from a Reactome reaction
describing Hh variant ubiquitination in which ERLEC1 participates.
- term:
id: GO:0044322
label: endoplasmic reticulum quality control compartment
evidence_type: TAS
original_reference_id: Reactome:R-HSA-8866542
review:
summary: >-
TAS annotation from Reactome (R-HSA-8866542: VCP-catalyzed ATP
hydrolysis promotes the translocation of misfolded CFTR into the
cytosol). ERLEC1 is part of the ERAD machinery for misfolded CFTR,
consistent with ERQC localization.
action: ACCEPT
reason: >-
Duplicate ERQC localization annotation from a Reactome reaction
describing CFTR ERAD in which ERLEC1 participates as cargo receptor.
- term:
id: GO:0044322
label: endoplasmic reticulum quality control compartment
evidence_type: TAS
original_reference_id: Reactome:R-HSA-8866546
review:
summary: >-
TAS annotation from Reactome (R-HSA-8866546: RNF5 and RNF185
ubiquitinate misfolded CFTR). ERLEC1 operates within the ERQC
as part of the CFTR ERAD pathway.
action: ACCEPT
reason: >-
Duplicate ERQC localization annotation from a Reactome reaction
in the CFTR ERAD pathway.
- term:
id: GO:0044322
label: endoplasmic reticulum quality control compartment
evidence_type: TAS
original_reference_id: Reactome:R-HSA-8866551
review:
summary: >-
TAS annotation from Reactome (R-HSA-8866551: CFTR binds components
of the ERAD machinery for ubiquitination and degradation). ERLEC1
is one of the ERAD components that binds misfolded CFTR in the ERQC.
action: ACCEPT
reason: >-
Duplicate ERQC localization annotation from a Reactome reaction
describing CFTR binding to ERAD components including ERLEC1.
- term:
id: GO:0044322
label: endoplasmic reticulum quality control compartment
evidence_type: TAS
original_reference_id: Reactome:R-HSA-8866854
review:
summary: >-
TAS annotation from Reactome (R-HSA-8866854: VCP-catalyzed ATP
hydrolysis promotes the translocation of CFTR F508del into the
cytosol). ERLEC1 participates in ERAD of the common CF-causing
CFTR F508del mutation, within the ERQC.
action: ACCEPT
reason: >-
Duplicate ERQC localization annotation from a Reactome reaction
in the CFTR F508del ERAD pathway.
- term:
id: GO:0044322
label: endoplasmic reticulum quality control compartment
evidence_type: TAS
original_reference_id: Reactome:R-HSA-8866856
review:
summary: >-
TAS annotation from Reactome (R-HSA-8866856: RNF5 and RNF185
ubiquitinate CFTR F508del). ERLEC1 is part of the ERAD machinery
for CFTR F508del within the ERQC.
action: ACCEPT
reason: >-
Duplicate ERQC localization annotation from a Reactome reaction
in the CFTR F508del ERAD pathway.
- term:
id: GO:0044322
label: endoplasmic reticulum quality control compartment
evidence_type: TAS
original_reference_id: Reactome:R-HSA-8866857
review:
summary: >-
TAS annotation from Reactome (R-HSA-8866857: CFTR F508del binds
components of the ERAD machinery for ubiquitination and degradation).
ERLEC1 is an ERAD component that binds misfolded CFTR F508del.
action: ACCEPT
reason: >-
Duplicate ERQC localization annotation from a Reactome reaction
describing CFTR F508del ERAD.
- term:
id: GO:0044322
label: endoplasmic reticulum quality control compartment
evidence_type: TAS
original_reference_id: Reactome:R-HSA-9931264
review:
summary: >-
TAS annotation from Reactome (R-HSA-9931264: Active transport of
ubiquitinated CD274 from ER to cytosol). ERLEC1 participates in
ERAD of CD274 (PD-L1) within the ERQC.
action: ACCEPT
reason: >-
Duplicate ERQC localization annotation from a Reactome reaction
describing CD274 ERAD.
- term:
id: GO:0044322
label: endoplasmic reticulum quality control compartment
evidence_type: TAS
original_reference_id: Reactome:R-HSA-9931298
review:
summary: >-
TAS annotation from Reactome (R-HSA-9931298: Ubiquitination of CD274
by ERAD complex). ERLEC1 is part of the ERAD complex that
ubiquitinates CD274.
action: ACCEPT
reason: >-
Duplicate ERQC localization annotation from a Reactome reaction
describing CD274 ubiquitination by ERAD.
- term:
id: GO:0044322
label: endoplasmic reticulum quality control compartment
evidence_type: TAS
original_reference_id: Reactome:R-HSA-9931313
review:
summary: >-
TAS annotation from Reactome (R-HSA-9931313: p-S195-CD274 binds
ERAD complex). ERLEC1 is part of the ERAD complex that binds
phosphorylated CD274 for degradation.
action: ACCEPT
reason: >-
Duplicate ERQC localization annotation from a Reactome reaction
describing CD274 ERAD. Last of the 16 duplicate Reactome TAS
annotations for ERQC localization, all consistent with ERLEC1
role in ERAD.
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:18502753
review:
summary: >-
IPI annotation for protein binding based on Hosokawa et al.
(PMID:18502753), with UniProtKB:Q13438 (OS-9/OS9) as the interacting
partner. This paper showed that hXTP3-B forms an ER quality control
scaffold complex with OS-9, HRD1-SEL1L, and BiP. The interaction
between ERLEC1 and OS-9 is in the context of the ERAD scaffold complex.
While the interaction is real, GO:0005515 (protein binding) is
uninformative. A more specific term such as GO:0051787 (misfolded
protein binding) would capture the functional context, though the
direct interaction with OS-9 is more of a scaffold co-complex
interaction. The term could be modified to misfolded protein binding
to reflect ERLEC1 function, but since the with/from is OS-9 (a
co-complex partner, not a misfolded substrate), the annotation as
stated is simply documenting a physical interaction.
action: MODIFY
reason: >-
GO:0005515 (protein binding) is uninformative per curation guidelines.
ERLEC1 binds misfolded glycoproteins as a cargo receptor. The more
informative term is GO:0051787 (misfolded protein binding), which
captures ERLEC1 core molecular function of recognizing misfolded
glycoprotein substrates for ERAD.
proposed_replacement_terms:
- id: GO:0051787
label: misfolded protein binding
supported_by:
- reference_id: PMID:18502753
supporting_text: >-
this large ER quality control scaffold complex, containing ER lectins,
a chaperone, and a ubiquitin ligase, provides a platform for the
recognition and sorting of misfolded glycoproteins as well as
nonglycosylated proteins prior to retrotranslocation into the cytoplasm
for degradation
- term:
id: GO:0005515
label: protein binding
evidence_type: IDA
original_reference_id: PMID:16531414
review:
summary: >-
IDA annotation for protein binding based on Cruciat et al.
(PMID:16531414). This paper identified Erlectin as a protein that
interacts with Kremen2 (KREMEN2), a coreceptor for Dickkopf1 in Wnt
signaling. The interaction with Kremen2 is glycosylation-dependent
(abolished by Kremen2 deglycosylation) and requires the second MRH
domain of Erlectin (G379S mutation abolishes binding). Overexpression
of Erlectin inhibited transport of Krm2 to the cell surface. This
interaction reflects ERLEC1 lectin activity in glycoprotein quality
control. GO:0005515 is uninformative; the functional activity is
better captured by misfolded protein binding or N-glycan recognition.
action: MODIFY
reason: >-
GO:0005515 (protein binding) is uninformative per curation guidelines.
The interaction with Kremen2 via N-glycan recognition represents
ERLEC1 lectin function in the ER. The more informative term is
GO:0051787 (misfolded protein binding), reflecting ERLEC1 role in
recognizing glycoproteins for ER quality control.
proposed_replacement_terms:
- id: GO:0051787
label: misfolded protein binding
supported_by:
- reference_id: PMID:16531414
supporting_text: >-
Erlectin functions in N-glycan recognition in the endoplasmic
reticulum, suggesting that it may regulate glycoprotein traffic
- reference_id: PMID:16531414
supporting_text: >-
It contains two MRH domains, of which one is essential for Krm2
binding, and this interaction is abolished by Krm2 deglycosylation
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:18264092
review:
summary: >-
IPI annotation for protein binding based on Christianson et al.
(PMID:18264092), with multiple interacting partners (UniProtKB:P11021
HSPA5/BiP, UniProtKB:Q86TM6 SYVN1/HRD1, UniProtKB:Q9UBV2 SEL1L).
This paper showed that XTP3-B binds to ERAD substrates and through
SEL1L to HRD1. The MRH domains are required for interaction with
SEL1L but not with substrate. XTP3-B and OS-9 are components of
distinct, partially redundant quality control surveillance pathways.
GO:0005515 is uninformative; ERLEC1 interactions with SEL1L and
HRD1 reflect its role as a substrate adaptor for the ERAD ubiquitin
ligase complex.
action: MODIFY
reason: >-
GO:0005515 (protein binding) is uninformative per curation guidelines.
The interactions documented here are functionally significant: ERLEC1
binding to SEL1L and HRD1 via its MRH domains reflects its role as
a substrate adaptor that bridges misfolded glycoproteins to the E3
ubiquitin ligase complex. The most informative molecular function
term would be GO:0051787 (misfolded protein binding), capturing
ERLEC1 core activity of recognizing misfolded substrates.
proposed_replacement_terms:
- id: GO:0051787
label: misfolded protein binding
supported_by:
- reference_id: PMID:18264092
supporting_text: >-
OS-9 and XTP3-B/Erlectin are ER-resident glycoproteins that bind to
ERAD substrates and, through the SEL1L adaptor, to the
ER-membrane-embedded ubiquitin ligase Hrd1
- reference_id: PMID:18264092
supporting_text: >-
Both proteins contain conserved mannose 6-phosphate receptor homology
(MRH) domains, which are required for interaction with SEL1L, but not
with substrate
- term:
id: GO:0005788
label: endoplasmic reticulum lumen
evidence_type: IDA
original_reference_id: PMID:16531414
review:
summary: >-
IDA annotation for ER lumen localization based on Cruciat et al.
(PMID:16531414). This paper demonstrated by immunofluorescence and
mass spectrometry that Erlectin is a luminal resident protein of the
endoplasmic reticulum. ERLEC1 has a signal peptide (aa 1-33) and
lacks a transmembrane domain, consistent with a soluble ER lumen
protein.
action: ACCEPT
reason: >-
ER lumen localization is a well-established core feature of ERLEC1,
directly demonstrated by Cruciat et al. The IDA evidence is strong
and consistent with the protein sequence (signal peptide, no TM
domain) and with other experimental studies.
supported_by:
- reference_id: PMID:16531414
supporting_text: >-
Like other members of the MRH family, Erlectin is a luminal resident
protein of the endoplasmic reticulum
- term:
id: GO:0005788
label: endoplasmic reticulum lumen
evidence_type: IDA
original_reference_id: PMID:18264092
review:
summary: >-
IDA annotation for ER lumen localization based on Christianson et al.
(PMID:18264092). This paper confirmed that XTP3-B/Erlectin is an
ER-resident glycoprotein, consistent with ER lumen localization
established by Cruciat et al. (PMID:16531414) and Hosokawa et al.
(PMID:18502753).
action: ACCEPT
reason: >-
Independent experimental confirmation of ER lumen localization by
a second research group. Consistent with all other evidence.
supported_by:
- reference_id: PMID:18264092
supporting_text: >-
OS-9 and XTP3-B/Erlectin are ER-resident glycoproteins that bind to
ERAD substrates and, through the SEL1L adaptor, to the
ER-membrane-embedded ubiquitin ligase Hrd1
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:16531414
review:
summary: >-
IPI annotation for protein binding based on Cruciat et al.
(PMID:16531414), with UniProtKB:Q8K1S7 (mouse Kremen2) as the
interacting partner. This paper identified Erlectin in a proteomic
approach as a protein that interacts with Kremen2. The interaction
is glycosylation-dependent and requires the MRH domain of Erlectin.
GO:0005515 is uninformative; this interaction reflects ERLEC1 lectin
activity in N-glycan recognition and glycoprotein quality control.
action: MODIFY
reason: >-
GO:0005515 (protein binding) is uninformative per curation guidelines.
The interaction with glycosylated Kremen2 via the MRH domain reflects
ERLEC1 lectin function. The more informative term is GO:0051787
(misfolded protein binding), as ERLEC1 recognizes glycoproteins in
the context of ER quality control.
proposed_replacement_terms:
- id: GO:0051787
label: misfolded protein binding
supported_by:
- reference_id: PMID:16531414
supporting_text: >-
It contains two MRH domains, of which one is essential for Krm2
binding, and this interaction is abolished by Krm2 deglycosylation
- reference_id: PMID:16531414
supporting_text: >-
The overexpression of Erlectin inhibits transport of Krm2 to the
cell surface
- term:
id: GO:0051787
label: misfolded protein binding
evidence_type: IDA
original_reference_id: PMID:18264092
review:
summary: >-
NEW annotation proposed for GO:0051787 (misfolded protein binding).
Multiple studies demonstrate that ERLEC1/XTP3-B binds to misfolded
glycoproteins in the ER. Christianson et al. (PMID:18264092) showed
that XTP3-B binds to ERAD substrates (mutant alpha1-antitrypsin NHK).
Hosokawa et al. (PMID:18502753) showed that hXTP3-B forms a scaffold
complex for recognition and sorting of misfolded glycoproteins and
nonglycosylated proteins. Groisman et al. (PMID:21062743) demonstrated
that substrate association with XTP3-B depends on mannose trimming.
This term is more informative than the generic GO:0005515 (protein
binding) annotations currently present and accurately captures
ERLEC1 core molecular function as a lectin that recognizes misfolded
glycoprotein substrates for ERAD.
action: NEW
reason: >-
GO:0051787 (misfolded protein binding) is the most informative
molecular function term for ERLEC1. It replaces the uninformative
GO:0005515 (protein binding) annotations and provides the correct
replacement for the obsolescent GO:0051082 (unfolded protein binding).
ERLEC1 specifically binds misfolded glycoproteins (not simply unfolded
polypeptides) as a cargo receptor for ERAD.
additional_reference_ids:
- PMID:18502753
- PMID:21062743
supported_by:
- reference_id: PMID:18264092
supporting_text: >-
OS-9 and XTP3-B/Erlectin are ER-resident glycoproteins that bind to
ERAD substrates and, through the SEL1L adaptor, to the
ER-membrane-embedded ubiquitin ligase Hrd1
- reference_id: PMID:18502753
supporting_text: >-
this large ER quality control scaffold complex, containing ER lectins,
a chaperone, and a ubiquitin ligase, provides a platform for the
recognition and sorting of misfolded glycoproteins as well as
nonglycosylated proteins prior to retrotranslocation into the cytoplasm
for degradation
- reference_id: PMID:21062743
supporting_text: >-
substrate association with XTP3-B and with the E3 ubiquitin ligases
HRD1 and SCF(Fbs2) was inhibited
- term:
id: GO:0097466
label: ubiquitin-dependent glycoprotein ERAD pathway
evidence_type: TAS
original_reference_id: PMID:21062743
review:
summary: >-
NEW annotation proposed for GO:0097466 (ubiquitin-dependent glycoprotein
ERAD pathway). This term is more specific than GO:0036503 (ERAD pathway)
and captures the fact that ERLEC1 specifically functions in the
glycoprotein-specific branch of ERAD. Groisman et al. (PMID:21062743)
showed that mannose trimming of N-glycans is required for substrate
delivery from EDEM1 to XTP3-B, establishing ERLEC1 as a lectin that
acts specifically in glycoprotein ERAD. The broader GO:0036503 (ERAD
pathway) annotation should be retained as well, since Hosokawa et al.
(PMID:18502753) showed that the long isoform also affects ERAD of the
non-glycosylated NHK-QQQ substrate.
action: NEW
reason: >-
GO:0097466 is a more specific child term of GO:0036503 that precisely
captures ERLEC1 role in the glycoprotein-specific branch of ERAD,
where it recognizes trimmed N-glycans on misfolded substrates. This
provides higher annotation specificity while the broader ERAD pathway
term is retained for the non-glycoprotein ERAD role.
additional_reference_ids:
- PMID:18264092
- PMID:18502753
supported_by:
- reference_id: PMID:21062743
supporting_text: >-
Our results suggest that mannose trimming enables delivery of a
substrate glycoprotein from EDEM1 to late ERAD steps through
association with XTP3-B
- reference_id: PMID:21062743
supporting_text: >-
the mannosidase inhibitor kifunensine or ERManI knockdown do not
affect binding of an ERAD substrate glycoprotein to EDEM1. In
contrast, substrate association with XTP3-B and with the E3
ubiquitin ligases HRD1 and SCF(Fbs2) was inhibited
core_functions:
- description: >-
ERLEC1 functions as a lectin-based cargo receptor and context-dependent triage
factor in the ERAD pathway. Its C-terminal MRH domain (MRH2) binds
Man9GlcNAc2 (M9) and Man5-type high-mannose N-glycans, specifically
recognizing a terminal alpha-1,6-linked mannose motif that is exposed during
progressive demannosylation of misfolded glycoproteins (DOI:10.1093/glycob/cwp182,
DOI:10.1111/febs.12157). ERLEC1 delivers recognized substrates to the
HRD1-SEL1L ubiquitin ligase complex for retrotranslocation and proteasomal
degradation. Mannose trimming by ER mannosidase I is required for substrate
delivery from EDEM1 to ERLEC1. SEL1L stabilizes ERLEC1 protein within the
ERAD complex (DOI:10.1111/febs.12157). Genetic studies reveal that ERLEC1 and
OS9 have redundant roles in promoting glycoprotein ERAD but antagonistic roles
regarding non-glycosylated substrates: ERLEC1 inhibits degradation of
non-glycosylated proteins, with OS9 counteracting this inhibition, thereby
tuning ERAD substrate selectivity and fidelity (DOI:10.1016/j.molcel.2018.03.026).
molecular_function:
id: GO:0051787
label: misfolded protein binding
directly_involved_in:
- id: GO:0036503
label: ERAD pathway
- id: GO:0097466
label: ubiquitin-dependent glycoprotein ERAD pathway
- id: GO:0030970
label: retrograde protein transport, ER to cytosol
locations:
- id: GO:0005788
label: endoplasmic reticulum lumen
- id: GO:0044322
label: endoplasmic reticulum quality control compartment
supported_by:
- reference_id: PMID:18264092
supporting_text: >-
OS-9 and XTP3-B/Erlectin are ER-resident glycoproteins that bind to
ERAD substrates and, through the SEL1L adaptor, to the
ER-membrane-embedded ubiquitin ligase Hrd1
- reference_id: PMID:21062743
supporting_text: >-
Our results suggest that mannose trimming enables delivery of a
substrate glycoprotein from EDEM1 to late ERAD steps through
association with XTP3-B
- reference_id: PMID:18502753
supporting_text: >-
this large ER quality control scaffold complex, containing ER lectins,
a chaperone, and a ubiquitin ligase, provides a platform for the
recognition and sorting of misfolded glycoproteins as well as
nonglycosylated proteins prior to retrotranslocation into the cytoplasm
for degradation
references:
- id: GO_REF:0000002
title: Gene Ontology annotation through association of InterPro records with GO
terms
findings: []
- id: GO_REF:0000033
title: Annotation inferences using phylogenetic trees
findings: []
- id: GO_REF:0000044
title: Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location
vocabulary mapping, accompanied by conservative changes to GO terms applied by
UniProt
findings: []
- id: GO_REF:0000117
title: Electronic Gene Ontology annotations created by ARBA machine learning models
findings: []
- id: PMID:16531414
title: The MRH protein Erlectin is a member of the endoplasmic reticulum synexpression
group and functions in N-glycan recognition.
findings: []
- id: PMID:18264092
title: OS-9 and GRP94 deliver mutant alpha1-antitrypsin to the Hrd1-SEL1L ubiquitin
ligase complex for ERAD.
findings: []
- id: PMID:18502753
title: Human XTP3-B forms an endoplasmic reticulum quality control scaffold with
the HRD1-SEL1L ubiquitin ligase complex and BiP.
findings: []
- id: PMID:21062743
title: Mannose trimming is required for delivery of a glycoprotein from EDEM1 to
XTP3-B and to late endoplasmic reticulum-associated degradation steps.
findings: []
- id: PMID:25660456
title: Identification of ERAD components essential for dislocation of the null Hong
Kong variant of Ξ±-1-antitrypsin (NHK).
findings: []
- id: DOI:10.1093/glycob/cwp182
title: Human XTP3-B binds to alpha1-antitrypsin variant nullHong Kong via the C-terminal
MRH domain in a glycan-dependent manner.
findings:
- statement: >-
ERLEC1/XTP3-B C-terminal MRH domain mediates binding to Man9GlcNAc2 and
Man5-type high-mannose N-glycans with specificity for a terminal
ManΞ±1,6Man motif
- statement: >-
Glycan-dependent binding to misfolded alpha1-antitrypsin NHK was abolished
by Endo H treatment (p < 0.001)
- id: DOI:10.1111/febs.12157
title: Endoplasmic reticulum lectin XTP3-B inhibits endoplasmic reticulum-associated
degradation of a misfolded alpha1-antitrypsin variant.
findings:
- statement: >-
ERLEC1/XTP3-B inhibits ERAD of misfolded alpha1-antitrypsin NHK carrying
M9 glycans, acting as a negative regulator that may protect newly
synthesized glycoproteins from premature degradation
- statement: >-
Lectin activity is required for substrate engagement but not for SEL1L
association
- statement: >-
SEL1L depletion causes accelerated ERLEC1 degradation (~40% protein loss
over 10 hours in cycloheximide chase, mRNA unchanged), indicating SEL1L
stabilizes ERLEC1 protein
- id: DOI:10.1016/j.molcel.2018.03.026
title: Redundant and antagonistic roles of XTP3B and OS9 in decoding glycan and non-glycan
degrons in ER-associated degradation.
findings:
- statement: >-
OS9 and XTP3B redundantly promote glycoprotein ERAD and stabilize the
SEL1L-HRD1 complex
- statement: >-
XTP3B strongly inhibits degradation of non-glycosylated substrates, with
OS9 antagonizing this inhibition
- statement: >-
Relative abundance of OS9 vs XTP3B and distribution of glycan vs
non-glycan degrons within substrates shapes ERAD fidelity and
processivity
- id: DOI:10.1093/glycob/cwq013
title: The role of MRH domain-containing lectins in ERAD.
findings:
- statement: >-
Review placing ERLEC1/XTP3-B and OS-9 as MRH-domain lectins that decode
glycan-based degradation signals and associate with the SEL1L-HRD1 ERAD
complex
- id: DOI:10.1038/s41467-024-45633-0
title: SEL1L-HRD1 interaction is required to form a functional HRD1 ERAD complex.
findings:
- statement: >-
SEL1L hypomorphic variant SEL1L-S658P attenuates SEL1L-HRD1 interaction
(~5-fold reduction) while preserving SEL1L-lectin interactions with
OS9/ERLEC1
- statement: >-
ERLEC1 interaction with SEL1L is maintained even when the overall ERAD
complex is compromised
- id: Reactome:R-HSA-5362412
title: SYVN1 ubiquitinates Hh C-terminal fragments
findings: []
- id: Reactome:R-HSA-5362437
title: C-terminal Hh fragments are bound by lectins
findings: []
- id: Reactome:R-HSA-5362441
title: C-terminal Hh fragments are recruited to SEL1:SYVN1 at the ER membrane
findings: []
- id: Reactome:R-HSA-5362450
title: Hh processing variants bind lectins
findings: []
- id: Reactome:R-HSA-5362459
title: VCP-catalyzed ATP hydrolysis promotes the translocation of Hh-C into the
cytosol
findings: []
- id: Reactome:R-HSA-5387386
title: Hh processing variants are recruited to SEL1:SYVN at the ER membrane
findings: []
- id: Reactome:R-HSA-5387389
title: Hh processing variants are translocated to the cytosol in a VCP-dependent
manner
findings: []
- id: Reactome:R-HSA-5483238
title: Hh processing variants are ubiquitinated
findings: []
- id: Reactome:R-HSA-8866542
title: VCP-catalyzed ATP hydrolysis promotes the translocation of misfolded CFTR
into the cytosol
findings: []
- id: Reactome:R-HSA-8866546
title: RNF5 and RNF185 ubiquitinate misfolded CFTR
findings: []
- id: Reactome:R-HSA-8866551
title: CFTR binds components of the ERAD machinery for ubiquitination and degradation
findings: []
- id: Reactome:R-HSA-8866854
title: VCP-catalyzed ATP hydrolysis promotes the translocation of CFTR F508del into
the cytosol
findings: []
- id: Reactome:R-HSA-8866856
title: RNF5 and RNF185 ubiquitinate CFTR F508del
findings: []
- id: Reactome:R-HSA-8866857
title: CFTR F508del binds components of the ERAD machinery for ubiquitination and
degradation
findings: []
- id: Reactome:R-HSA-9931264
title: Active transport of ubiquitinated CD274 from ER to cytosol
findings: []
- id: Reactome:R-HSA-9931298
title: Ubiquitination of CD274 by ERAD complex
findings: []
- id: Reactome:R-HSA-9931313
title: p-S195-CD274 binds ERAD complex
findings: []